"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,WO,A1,WO 2012/066330 A1,100-891-581-540-387,2012-05-24,2012,GB 2011052238 W,2011-11-16,US 41476710 P,2010-11-17,COMPOUNDS USEFUL AS A2A RECEPTOR INHIBITORS,"According to the invention there is provided a compound of formula I for use in the treatment of a condition or disorder ameliorated by the inhibition of the A 2a receptor, wherein the compound of formula I has the structure, wherein, X, A 1 , A 2 , R 1 and B 1 to B 5 have meanings given in the description.",HEPTARES THERAPEUTICS LTD;;MASON JONATHAN STEPHEN;;ANDREWS STEPHEN PHILIPPE;;CONGREVE MILES STUART,MASON JONATHAN STEPHEN;;ANDREWS STEPHEN PHILIPPE;;CONGREVE MILES STUART,,https://lens.org/100-891-581-540-387,Patent Application,yes,28,9,1,1,0,A61K31/352;;A61K31/427;;A61K31/517;;A61P25/28;;Y02A50/30,A61K31/35;;A61K31/517;;A61P25/28,,31,20,118-902-231-113-814;;015-848-123-664-142;;007-825-957-373-93X;;023-103-617-449-665;;048-989-499-244-089;;128-158-072-964-733;;089-996-350-178-258;;001-392-130-374-249;;057-393-239-160-275;;031-206-250-281-385;;049-984-615-855-375;;094-203-655-035-520;;096-086-179-687-335;;091-042-651-245-244;;149-788-858-304-284;;091-975-209-996-509;;013-371-077-225-326;;015-651-686-389-616;;011-781-581-063-521;;045-149-256-448-908,10.1002/jhet.5570370409;;20405927;;10.1021/jm100240h;;pmc2865168;;10.1152/ajpheart.1999.276.2.h341;;9950832;;10.1152/ajpheart.1999.276.3.h1113;;10070100;;10.2165/00003495-200161100-00002;;11558828;;9443164;;18537674;;pmc2423946;;10.2174/138161208784480090;;10.1517/13543784.12.8.1335;;12882620;;10.1517/eoid.12.8.1335.21771;;11880527;;pmc6758877;;10.1523/jneurosci.22-05-01967.2002;;14504416;;10.1159/000072882;;16871530;;10.1002/art.21974;;10.1002/ddr.1130;;11283304;;10.1146/annurev.neuro.24.1.31;;10.1097/01.nt.0000347512.59023.8f;;pmc3463109;;10.1038/nrd1983;;16518376;;15078215;;10.2174/1568026043450998;;10.1002/(sici)1098-2299(199811/12)45:3/4<166::aid-ddr12>3.0.co;2-p;;10.1016/j.jacc.2007.07.019;;17936154;;18926433;;10.1016/j.cardfail.2008.08.010;;2218494;;10.1126/science.2218494,"DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KHILYA, V. P. ET AL: ""Synthesis and hypolipidemic activity of 3-(4-thiazolyl)-6-alkyl-7-alkoxychromones"", XP002672153, retrieved from STN Database accession no. 1982:85461;;PARKANYI C ET AL: ""Synthesis of 5-chloro-2-methyl-3-(5-methylthiazol-2-yl)-4(3H)-quinazo linone and related compounds with potential biological activity"", JOURNAL OF HETEROCYCLIC CHEMISTRY 2000 US, vol. 37, no. 4, 2000, pages 725 - 729, XP002672154, ISSN: 0022-152X;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MISRA, SOBHA: ""Some 2-phenyl-3-(4-substituted-1,3-thiazol-2-yl)-4-quinazolinones as CNS active agents"", XP002672155, retrieved from STN Database accession no. 1983:126023;;DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; JAIN, MEGH KUMAR ET AL: ""Antimalarials in quinazolone series"", XP002672156, retrieved from STN Database accession no. 1955:4915;;CARLSSON J ET AL: ""Structure-based discovery of A2A adenosine receptor ligands"", JOURNAL OF MEDICINAL CHEMISTRY 20100513 AMERICAN CHEMICAL SOCIETY USA LNKD- DOI:10.1021/JM100240H, vol. 53, no. 9, 13 May 2010 (2010-05-13), pages 3748 - 3755, XP002672157, ISSN: 0022-2623;;CHEMICAL & ENGINEERING NEWS, vol. 83, no. 25, 2005;;NORTON ET AL., AM J PHYSIOL., vol. 276, 1999, pages H341 - 9;;AUCHAMPACH; BOLLI, AM J PHYSIOL., vol. 276, 1999, pages H 1113 - 6;;COSTELLO-BOERRIGTER ET AL., MED CLIN NORTH AM., vol. 87, no. 2, March 2003 (2003-03-01), pages 475 - 91;;GOTTLIEB, DRUGS, vol. 61, no. 10, 2001, pages 1387 - 93;;FEOKTISTOV ET AL., PHARMACOL. REV., vol. 49, 1997, pages 381 - 402;;CUNHA, CURR PHARM DES., vol. 14, no. 15, 2008, pages 1512 - 1524;;TUITE P, J. EXPERT OPIN. INVESTIG. DRUGS., vol. 12, 2003, pages 1335 - 52;;POPOLI P. ET AL., J NEUROSCI., vol. 22, 2002, pages 1967 - 75;;DALL'LGNA ET AL., EXPERIMENTAL NEUROLOGY, 2007, pages 241 - 245;;JENNER P., J NEUROL., vol. 247, no. 2, 2000, pages 1143 - 50;;HAPPE S ET AL., NEUROPSYCHOBIOLOGY, vol. 48, 2003, pages 82 - 6;;ARTHRITIS & RHEUMATISM, vol. 54, no. 8, 2006, pages 2632 - 2642;;STONE TW., DRAG. DEV. RES., vol. 52, 2001, pages 323 - 330;;DUNWIDDIE TV ET AL., ANN. REV. NEUROSCI., vol. 24, 2001, pages 31 - 55;;KUROKOWA ET AL., 2009 NEUROSCIENCE MEETING PLANNER, 2009;;JACOBSEN; GAO: ""Reviews Drug Discovery"", NATURE, vol. 5, 2006, pages 247 - 264;;ZABLOCKI ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 4, 2004, pages 839 - 854;;WOLFF ET AL., DRUG DEV. RES, vol. 45, 1998, pages 166;;GIVERTZ ET AL., J. AM. COLL. CARDIOL., vol. 50, 2007, pages 1551;;COTTER ET AL., JOURNAL OF CARDIAC FAILURE, vol. 8, 2008, pages 631 - 640;;BUNDEGAARD, H.: ""Design of Prodrugs"", 1985, ELSEVIER, pages: 1 - 92;;REMINGTON: ""The Science and Practice of Pharmacy, 19th ed."", 1995, MACK PRINTING COMPANY;;LANGER, SCIENCE, vol. 249, 1990, pages 1527;;J W F MCOMIE,: ""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;T.W. GREENE; P.G.M. WUTZ: ""Protective Groups in Organic Synthesis, 3rd edition,"", 1999, WILEY-INTERSCIENCE",PENDING
2,US,A1,US 2003/0025996 A1,150-025-258-107-332,2003-02-06,2003,US 16141702 A,2002-06-03,US 16141702 A;;US 29550001 P,2001-06-01,Autostereoscopic display system and components therefor,"
   A glasses-free autostereoscopic viewing environment based on a large-diameter, concave vacuum-controlled mirror allows the user to view and interact with a floating hologram-like image in real time, without the use of special peripheral devices such as shutter glasses. This technology creates the unique ability to vary focal length over a wide range, yielding superior quality stereo images. Compatibility allows PCs or high-end graphics workstations to drive the system. It also easily interfaces with most haptic devices. A telepresence embodiment allows remote viewing of a live or recorded scene while giving the user the feeling of immersion at the remote site. The remote system consists of a site sensor platform containing stereo cameras and microphones. The platform's patented ability to pan, tilt, and/or roll delivers enhanced control of the captured visual and aural images of the remote site. When captured, any telecommunications system (e.g. mobile phone, Internet, or ISDN) can deliver these images to the home site. 
",ANDREWS ROBERT E.;;DONKIN THOMAS R.;;MCKAY STUART;;MASON STEVEN,ANDREWS ROBERT E;;DONKIN THOMAS R;;MCKAY STUART;;MASON STEVEN,,https://lens.org/150-025-258-107-332,Patent Application,yes,0,4,1,1,0,G02B26/0825;;H04N13/393;;G02B30/26;;G02B26/0825;;H04N13/393;;G02B30/26,G02B26/08;;G02B30/26;;H04N13/00,359/472;;359/462;;359/464,0,0,,,,DISCONTINUED
3,GB,B,GB 2551945 B,174-492-555-118-672,2021-09-08,2021,GB 201522431 A,2015-12-18,GB 201522431 A,2015-12-18,Novel GLP-1 receptor agonist peptides,,HEPTARES THERAPEUTICS LTD,STEVE ANDREWS;;MILES STUART CONGREVE;;ANDREA BORTOLATO;;JONATHAN STEPHEN MASON,,https://lens.org/174-492-555-118-672,Granted Patent,no,2,0,3,3,0,A61K38/00;;A61K38/08;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;C07K7/06;;C07K14/605;;C07K7/06,C07K7/06;;A61K38/08;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00,,0,0,,,,ACTIVE
4,GB,A,GB 2551945 A,196-318-960-837-851,2018-01-10,2018,GB 201522431 A,2015-12-18,GB 201522431 A,2015-12-18,Novel GLP-1 receptor agonist peptides,"A compound of formula (I): (I) wherein Q is optionally substituted phenyl or monocyclic heteroaryl; x is an integer from 1 to 3; R1 & R2 are hydrogen or C1-6 alkyl, or form a ring; aa1 is an amino acid; G is glycinyl;T is L-threoninyl; aa2 is an amino acid; W is L-serinyl or 2,3-diaminopropionyl; aa3 is an amino acid; aa4 is an amino acid; aa5 is a linking group; Z is hydrogen, -COOR8 or -CONR9R10; R8, R9 and R10 are hydrogen or C1-6 alkyl; or a tautomeric or stereochemically isomeric form or a prodrug, salt or zwitterion thereof. The compounds of formula (I) are Glucagon-like peptide-1 (GLP-1) receptor agonist peptides and are useful in treating diseases or conditions mediated by insulin, such as diabetes mellitus type 1 or 2. The invention further relates to compositions containing said peptides and processes for their preparation.",HEPTARES THERAPEUTICS LTD,STEVE ANDREWS;;MILES STUART CONGREVE;;ANDREA BORTOLATO;;JONATHAN STEPHEN MASON,,https://lens.org/196-318-960-837-851,Patent Application,no,2,9,3,3,0,A61K38/00;;A61K38/08;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00;;C07K7/06;;C07K14/605;;C07K7/06,C07K7/06;;A61K38/08;;A61P3/04;;A61P3/06;;A61P3/10;;A61P9/00,,0,0,,,,ACTIVE
5,US,B2,US 10988455 B2,009-845-794-998-281,2021-04-27,2021,US 201816161409 A,2018-10-16,US 201816161409 A;;US 201615344048 A;;US 201514976738 A;;US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-triazine-4-amine derivatives","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4 b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-13),https://lens.org/009-845-794-998-281,Granted Patent,yes,28,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04;;A61K31/4427;;A61K31/506;;A61K31/53;;A61K31/5355;;A61K31/5377;;A61K31/5386;;A61P35/00;;C07D253/07;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D403/14;;C07D405/04;;C07D405/10;;C07D413/04;;C07D413/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D487/04,,55,40,023-103-617-449-665;;173-468-323-248-682;;045-255-739-470-754;;049-984-615-855-375;;049-844-139-775-117;;089-996-350-178-258;;162-922-566-598-984;;116-389-116-814-538;;130-680-203-388-320;;082-786-111-595-062;;096-086-179-687-335;;031-369-160-374-939;;018-503-924-256-865;;128-158-072-964-733;;028-936-953-315-808;;038-312-590-427-698;;015-651-686-389-616;;048-989-499-244-089;;031-206-250-281-385;;053-688-150-554-166;;099-808-125-101-096;;066-456-059-551-748;;149-788-858-304-284;;043-050-631-124-639;;045-149-256-448-908;;002-261-516-474-310;;042-838-227-952-202;;117-852-382-648-315;;008-392-397-583-861;;007-825-957-373-93X;;057-393-239-160-275;;043-181-134-051-352;;136-814-904-308-708;;007-035-561-306-128;;167-584-024-775-184;;094-203-655-035-520;;001-392-130-374-249;;086-152-334-791-678;;076-801-301-292-463;;020-742-492-212-69X,10.1152/ajpheart.1999.276.3.h1113;;10070100;;10.1007/978-3-540-89615-9_19;;19639295;;10.1002/chin.200437037;;16871530;;10.1002/art.21974;;10.1016/s0025-7125(02)00181-5;;12693735;;18537674;;pmc2423946;;10.2174/138161208784480090;;17007839;;10.1016/j.expneurol.2006.08.008;;10.1002/jps.2600670554;;205646;;10.1038/nbt0394-320;;1795036;;10.1016/s0021-9673(01)88448-x;;11283304;;10.1146/annurev.neuro.24.1.31;;10.1002/chin.199033200;;pmc3437034;;22961543;;10.1093/brain/aws225;;9443164;;9732378;;18029023;;10.1016/j.pharmthera.2007.09.002;;10.1016/j.jacc.2007.07.019;;17936154;;10.2165/00003495-200161100-00002;;11558828;;14504416;;10.1159/000072882;;pmc2756472;;10.1016/j.it.2009.04.001;;19427267;;10.1124/jpet.108.149617;;19332567;;23675382;;pmc3646240;;10.3389/fgene.2013.00076;;pmc3463109;;10.1038/nrd1983;;16518376;;10.1007/pl00007760;;10991665;;2218494;;10.1126/science.2218494;;10.1021/jo0611059.s001;;16930076;;10.1021/jo0611059;;17674488;;10.1631/jzus.2007.b0526;;pmc1906601;;17684118;;10.1124/jpet.107.121962;;17274623;;10.1021/ol062903o;;10.1021/ol062903o.s001;;10.1152/ajpheart.1999.276.2.h341;;9950832;;11880527;;pmc6758877;;10.1523/jneurosci.22-05-01967.2002;;10.1021/ol035681s.s001;;10.1021/ol035681s;;14602009;;10.1021/ja027965y;;12405811;;10982777;;10.1053/gast.2000.16502;;10.3987/r-1982-10-1895;;10.1002/ddr.1130;;10.1517/13543784.12.8.1335;;12882620;;10.1517/eoid.12.8.1335.21771;;10.1038/bjp.2008.361;;pmc2579661;;18852693;;10.15227/orgsyn.078.0023;;19426761;;10.1016/j.pharmthera.2009.04.003;;pmc2743314,"Wolff Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.;;Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.;;2009 Meeting Planner, Society for Neuroscience, Chicago, IL, Program No. 714.4/B101.;;Auchampach et al., Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges. Am J Physiol. Mar. 1999;276(3 Pt 2):H1113-6.;;Bauer, Adenosine receptor ligands and PET imaging of the CNS. Handb Exp Pharrnacol. 2009;(193):617-42.;;Bennet et al., Cecil Textbook of Medicine, 20th edition. 1996;1:1004-101.;;Boovanahalli et al., Application of ionic liquid halide nucleophilicity for the cleavage of ethers: a green protocol for the regeneration of phenols from ethers. J Org Chem. May 14, 2004;69(10):3340-4.;;Bundgaard, Design of prodrugs. Elsevier, New York. pp. 1-92, (1985).;;Byrn et al., Solid-State Chemistry of Drugs, 2nd Edition. SSCI, Inc. of West LaFayette, (1999).;;Chan et al., Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis Rheum. Aug. 2006;54(8):2632-42.;;Costello-Boerrigter et al., Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. Med Clin North Am. Mar. 2003;87(2):475-91.;;Cunha et al., Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des. 2008;14(15):1512-24.;;Dall'Igna et al., Caffeine and adenosine A(2a) receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice. Exp Neurol. Jan. 2007;203(1):241-5.;;Davidson et al., Synthesis of as-triazines as potential antiviral agents. J Pharm Sci. May 1978;67(5):737-9.;;Dermer, Another Anniversary for the War on Cancer. Bio/Technology. 1994;12:320.;;Doig et al., Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine. J Chromatogr. Aug. 21, 1991;554(1-2):181-9.;;Dunwiddie et al., The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31-55.;;Eid et al., Reactions of 3-amino/substituted amino-6-benzyl-5-thioxo-and 5-chloro-1, 2, 4-triazines: Synthesis of 3,5-substituted diamino-1, 2, 4-triazines and 5-amino/substituted amino-8-benzyl-3-thioxo-s-triazolo [4, 3-d] [1, 2, 4] triazines. ChemInform. Aug. 1990;29(5):435-439.;;Eijkelkamp et al., Neurological perspectives on voltage-gated sodium channels. Brain. Sep. 2012;135(Pt 9):2585-612.;;Feoktistov et al., Adenosine A2B receptors. Pharmacol Rev. Dec. 1997;49(4):381-402.;;Freshney et al., Culture of Animal Cells, A Manual of Basic Technique. Alan R. Liss, Inc., New York, p. 4, (1983).;;Gellai et al., CVT-124, a novel adenosine A1 receptor antagonist with unique diuretic activity. J Pharmacol Exp Ther. Sep. 1998;286(3):1191-6.;;Gennaro, Remington, The Science and Practice of Pharmacy, 19th Edition. Mack Printing Company, Easton, (1995).;;Gessi et al., The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther. Jan. 2008;117(1):123-40.;;Givertz et al., The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. Oct. 16, 2007;50(16):1551-60.;;Gottlieb, Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs. 2001;61(10):1387-93.;;Greene et al., Protective Groups in Organic Synthesis, Third Edition. Wiley Interscience, New York, (1999).;;Happe et al., Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology. 2003;48(2):82-6.;;Haskó et al., A(2B) adenosine receptors in immunity and inflammation. Trends Immunol. Jun. 2009;30(6):263-70.;;Hodgson et al., Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther. Jul. 2009;330(1):294-303.;;Imbrici et al., Major channels involved in neuropsychiatric disorders and therapeutic perspectives. Front Genet. May 7, 2013;4:76.;;Jacobson et al., Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. Mar. 2006;5(3):247-64.;;Jenner, Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments. J Neurol. Apr. 2000;247 Suppl 2:II43-50.;;Langer, New methods of drug delivery. Science. Sep. 28, 1990;249(4976):1527-33.;;Lu et al., New Heterocycles Forming Reactions of Acyl Thioformanilides. Org Prep Proced Int. 1992;24(3):358-62.;;Magano et al., 2-(Diethylamino)ethanethiol, a new reagent for the odorless deprotection of aromatic methyl ethers. J Org Chem. Sep. 1, 2006;71(18):7103-5.;;Mahajam et al., Synthesis of 3-amino-5-substituted phenylamino-6-phenyl-1, 2, 4-triazines. Youji Huaxue. 1992;12:605-7.;;Mallikarjuna et al., Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines. J Zhejiang Univ Sci B. Jul. 2007;8(7):526-32.;;March, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Fourth Edition. Wiley Interscience, New York. pp. 131-133, (1992).;;McOmie, Protective Groups in Organic Chemistry. Plenum Press, New York, (1973).;;Mihara et al., Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyppyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson's disease and cognition. J Pharmacol Exp Ther. Nov. 2007;323(2):708-19.;;Murphy et al., One-pot synthesis of arylboronic acids and aryl trifluoroborates by Ir-catalyzed borylation of arenes. Org Lett. Mar. 1, 2007;9(5):757-60.;;Norton et al., Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart. Am J Physiol. Feb. 1999;276(2 Pt 2):H341-9.;;Popoli et al., Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. J Neurosci. Mar. 1, 2002;22(5):1967-75.;;Quach et al., Ligand- and base-free copper(II)-catalyzed C—A bond formation: cross-coupling reactions of organoboron compounds with aliphatic amines and anilines. Org Lett. Nov. 13, 2003;5(23):4397-400.;;Ryu et al., Phase-vanishing reactions that use fluorous media as a phase screen. Facile, controlled bromination of alkenes by dibromine and dealkylation of aromatic ethers by boron tribromide. J Am Chem Soc. Nov. 6, 2002;124(44):12946-7.;;Satoh et al., Activation of adenosine A1-receptor pathway induces edema formation in the pancreas of rats. Gastroenterology. Sep. 2000;119(3):829-36.;;Sharma et al., Synthesis of Benzo[5,6]cyclohept[1,2,3ij]isoquinolines as Rigid Congeners of Tetrahydropapaveroline. Heterocycles. 1982;19(10):1895-1901.;;Stone et al., Neuroprotection by A2A Receptor Antagonists. Drug Dev Res. Jan.-Feb. 2001;52(1-2):323-330.;;Tuite et al., Recent developments in the pharmacological treatment of Parkinson's disease. Expert Opin Investig Drugs. Aug. 2003;12(8):1335-52.;;Voith, L-DOPA. Chem Eng News. 2005, 83(25):60.;;Wilson, Adenosine receptors and asthma in humans. Brit J Pharmacol. Oct. 2008;155(4):485-486.;;Wolfe et al., Palladium-Catalyzed Amination of Aryl Halides and Aryl Triflates: N-Hexyl-2-Methyl-4-Methoxyaniline and N-Methyl-N-(4-Chlorophenyl) Aniline. Orgn Synth. 2004;vol. 10:423.;;Zhou et al., Adenosine signaling and the regulation of chronic lung disease. Pharmacol Ther. Jul. 2009;123(1):105-16.;;Zou et al., Study on the syntheses of new 1-o-chlorobenzoyl-3(5'-substituted phenylamino-6'-phenyl)-1', 2', 4'-triazinyl ureas. Chinese Journal of Chemistry. Aug. 2010;16(1):58-64.",ACTIVE
6,BR,A2,BR 112012019540 A2,022-551-153-378-143,2017-12-12,2017,BR 112012019540 A,2011-02-07,EP 2011051755 W;;US 30206010 P;;US 38176410 P,2010-02-05,"""composto, uso de um composto, método para tratamento de uma condição ou um distúrbio, método para mitigar dano renal, formulação farmacêutica, e, processo para a preparação de um composto""","composto, uso de um composto, método para tratamento de uma condição ou um distúrbio, método para mitigar dano renal, formulação farmacêutica, e, processo para a preparação de um composto. de acordo com a invenção é fornecido um composto da fórmula a1 que pode ser útil no tratamento de uma condição ou um distúrbio melhorada(o) pela inibição dos receptores a1-a2b ou, particularmente, ao a2a em que o composto da formula a1 tem a estrutura, em que, a representa cy1 ou heta; cy1 representa um sistema de anel carbocíclico de 5 a 14 membros aromático, totalmente saturado ou parcialmente insaturado que compreende um, dois ou três anéis, grupo cy1 este que é opcionalmente substituído por um ou mais substituintes r4; heta representa um grupo heterocíclico de 5 a 14 membros que pode ser aromático, totalmente saturado ou parcialmente insaturado, e que contém um ou mais heteroátomos selecionados de o, s e n, grupo heterocíclico este que pode compreender um, dois ou três anéis e grupo heta este que é opcionalmente substituído por um ou mais substituintes r4b; b representa um cy2 ou hetb; cy2 representa um sistema de anel carbocíclico de 3 a 10 membros aromático, totalmente saturado ou parcialmente insaturado que compreende um ou dois anéis, grupo cy2 este que é opcionalmente substituído por um ou mais substituintes r4c; hetb representa um grupo heterocíclico de 3 a 10 membros que pode ser aromático, totalmente saturado ou parcialmente insaturado, e que contém um ou mais heteroátomos selecionados de o, s e n, grupo heterocíclico este que pode compreender um ou dois anéis e grupo hetb este que é opcionalmente substituído por um ou mais substituintes r4d.",HEPTARES THERAPEUTICS LTD,CHRISTINE MARY RICHARDSON;;GILES ABERT BROWN;;JONATHAN STEPHEN MASON;;MILES STUART CONGREVE;;STEPHEN PHILIPPE ANDREWS,,https://lens.org/022-551-153-378-143,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,A61K31/53;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
7,SM,B,SM T201600198 B,022-745-158-691-265,2016-08-31,2016,SM 201600198 T,2016-06-23,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"DERIVATI DI 1,2,4-TRIAZINA-4-AMMINA",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/022-745-158-691-265,Unknown,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,,,0,0,,,,PENDING
8,US,A1,US 2016/0175314 A1,087-047-014-735-687,2016-06-23,2016,US 201514976738 A,2015-12-21,US 201514976738 A;;US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het a group is optionally substituted by one or more R 4d substituents",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/087-047-014-735-687,Patent Application,yes,0,1,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,A61K31/53;;A61K31/5377;;A61K31/5386,,0,0,,,,DISCONTINUED
9,CA,C,CA 2789279 C,175-080-568-755-780,2018-12-11,2018,CA 2789279 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/175-080-568-755-780,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
10,KR,A,KR 20180028550 A,008-982-961-833-05X,2018-03-16,2018,KR 20187006509 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,124--4- 124-TRIAZINE-4-AMINE DERIVATIVES,"본 발명은 A- A수용체, 또는 구체적으로 A수용체의 저해에 의해 완화되는 병태 또는 장애를 치료하는데 유용할 수 있는 식 A1의 화합물을 제공하며, 상기 식 A1의 화합물은, A가 Cy또는 Het이며; Cy이 1, 2 또는 3개의 고리를 포함하는, 5원 내지 14원의 방향족, 완전히 포화된 또는 부분 불포화된 카르보사이클릭 고리 시스템이되, 선택적으로 하나 이상의 R치환기로 치환되며; Het가, O, S 및 N으로부터 선택되는 하나 이상의 이종원자를 포함하는, 방향족이거나, 완전히 포화된 또는 부분 불포화된 것일 수 있는, 5원 내지 14원의 헤테로사이클릭기이되, 1, 2 또는 3개의 고리를 포함할 수 있으며, 선택적으로 하나 이상의 R치환기로 치환되며; B가 Cy또는 Het이며; Cy가 1 또는 2개의 고리를 포함하는, 3원 내지 10원의 방향족, 완전히 포화된 또는 부분 불포화된 카르보사이클릭 고리 시스템이되, 상기 Cy기는 하나 이상의 R치환기로 선택적으로 치환되며; Het가 O, S 및 N으로부터 선택되는 하나 이상의 이종원자를 포함하는, 방향족이거나, 완전히 포화된 또는 부분 불포화된 것일 수 있는, 3원 내지 10원의 헤테로사이클릭기이되, 상기 헤테로사이클릭기는 1 또는 2개의 고리를 포함할 수 있으며, 상기 Het기는 하나 이상의 R치환기로 선택적으로 치환되는, 구조를 가진다.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/008-982-961-833-05X,Patent Application,no,7,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D403/04;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/12;;C07D405/04;;C07D413/14,,0,0,,,,ACTIVE
11,US,B2,US 8809525 B2,044-480-899-478-872,2014-08-19,2014,US 201113576798 A,2011-02-07,US 201113576798 A;;US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-triazine-4-amine derivatives","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT;;HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/044-480-899-478-872,Granted Patent,yes,24,4,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04;;A61K31/444;;A61P25/16;;C07D253/07;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D403/14;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,544/182;;514/242,51,38,130-680-203-388-320;;023-103-617-449-665;;173-468-323-248-682;;045-255-739-470-754;;049-984-615-855-375;;049-844-139-775-117;;089-996-350-178-258;;162-922-566-598-984;;116-389-116-814-538;;082-786-111-595-062;;096-086-179-687-335;;031-369-160-374-939;;128-158-072-964-733;;028-936-953-315-808;;038-312-590-427-698;;015-651-686-389-616;;048-989-499-244-089;;031-206-250-281-385;;053-688-150-554-166;;099-808-125-101-096;;149-788-858-304-284;;043-050-631-124-639;;045-149-256-448-908;;002-261-516-474-310;;042-838-227-952-202;;117-852-382-648-315;;008-392-397-583-861;;007-825-957-373-93X;;057-393-239-160-275;;043-181-134-051-352;;136-814-904-308-708;;007-035-561-306-128;;167-584-024-775-184;;094-203-655-035-520;;001-392-130-374-249;;086-152-334-791-678;;076-801-301-292-463;;020-742-492-212-69X,10.1038/nbt0394-320;;10.1152/ajpheart.1999.276.3.h1113;;10070100;;10.1007/978-3-540-89615-9_19;;19639295;;10.1002/chin.200437037;;16871530;;10.1002/art.21974;;10.1016/s0025-7125(02)00181-5;;12693735;;18537674;;pmc2423946;;10.2174/138161208784480090;;17007839;;10.1016/j.expneurol.2006.08.008;;10.1002/jps.2600670554;;205646;;1795036;;10.1016/s0021-9673(01)88448-x;;11283304;;10.1146/annurev.neuro.24.1.31;;10.1002/chin.199033200;;9443164;;9732378;;18029023;;10.1016/j.pharmthera.2007.09.002;;10.1016/j.jacc.2007.07.019;;17936154;;10.2165/00003495-200161100-00002;;11558828;;14504416;;10.1159/000072882;;pmc2756472;;10.1016/j.it.2009.04.001;;19427267;;10.1124/jpet.108.149617;;19332567;;pmc3463109;;10.1038/nrd1983;;16518376;;10.1007/pl00007760;;10991665;;2218494;;10.1126/science.2218494;;10.1021/jo0611059.s001;;16930076;;10.1021/jo0611059;;17674488;;10.1631/jzus.2007.b0526;;pmc1906601;;17684118;;10.1124/jpet.107.121962;;17274623;;10.1021/ol062903o;;10.1021/ol062903o.s001;;10.1152/ajpheart.1999.276.2.h341;;9950832;;11880527;;pmc6758877;;10.1523/jneurosci.22-05-01967.2002;;10.1021/ol035681s.s001;;10.1021/ol035681s;;14602009;;10.1021/ja027965y;;12405811;;10982777;;10.1053/gast.2000.16502;;10.3987/r-1982-10-1895;;10.1002/ddr.1130;;10.1517/13543784.12.8.1335;;12882620;;10.1517/eoid.12.8.1335.21771;;10.1038/bjp.2008.361;;pmc2579661;;18852693;;10.15227/orgsyn.078.0023;;19426761;;10.1016/j.pharmthera.2009.04.003;;pmc2743314,"Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-101 O, 1996.;;Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.;;Dermer et al., Bio/Technology, 1994, 12:320.;;""L-DOPA"", Chem. Eng. News 2005, 83(25) 60.;;2009 Meeting Planner, Society for Neuroscience, Chicago, IL, Program No. 714.4/B101.;;Auchampach, et al., ""Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges"", Am. J. Physiol. 1999, 276, H1113-6.;;Bauer, et al., ""Adenosine Receptor Ligands and PET Imaging of the CNS"", Wilson and Mustafa ""Adenosine Receptors in Health and Disease"", Handbook of Experimental Pharmacology, 2009, Springer, Berlin, p. 617-642.;;Boovanahalli, et al., ""Application of Ionic Liquid Halide Nucleophilicity for the Cleavage of Ethers: A Green Protocol for the Regeneration of Phenols form Ethers"", J. Org. Chem. 2004, 69, 3340-4.;;Bundgaard, ""Design of prodrugs"", 1985, Elsevier, New York, p. 1-92.;;Byrn, et al., ""Solid-State Chemistry of Drugs"", 1999 2nd Ed., SSCI, Inc. of West LaFayette.;;Chan, et al., ""Adenosine A2A Receptors in Diffuse Dermal Fibrosis"", Arthris Rheum. 2006, 54, 2632-42.;;Costello-Boerrigter, et al., ""Revisiting sale and water retention: new diuretics, aquaretics, and natriuretics"", Med. Clin. North Am. 2003, 87, 475-91.;;Cunha, et al., ""Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders"", Curr. Pharm. Des. 2008, 14, 1512-24.;;Dall'igna, ""Caffeine and adenosine A2a receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice"", Exp. Neurol. 2007, 241-5.;;Davidson, et al., ""Synthesis of as-Triazines as Potential Antiviral Agents"", J Pharm. Sci. 1978, 67, 737-9.;;Doig, et al, ""Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine"", J. Chromatogr. 1991, 554, 181-9.;;Dunwiddie, et al., ""The Role and Regulation of Adenosine in the Central Nervous System"", Ann. Rev. Neurosci. 2001, 24, 31-55.;;Eid, et al., ""Reactions of 3-amino/substituted amino-6-benzyl-5-thioxo-and 5-chloro-1, 2, 4-triazines: Synthesis of 3,5-substituted diamino- 1, 2, 4-triazines and 5-amino/substituted amino-8-benzyl-3-thioxo-s-triazolo [4, 3-d] [1, 2, 4] triazines"", In. J. Chem. B 1990, 29B, 435-9.;;Feoktistov, et al., ""Adenosine A2B Receptors"", Pharmacol. Rev. 1997, 49, 381-402.;;Gellai, et al., ""CVT-124, a Novel Adenosine A1 Receptor Antagonist with Unique Diuretic Activity"", J. Pharmacol. Exp. Ther. 1998, 286, 1191-96.;;Gennaro, ""Remington, The Science and Practice of Pharmacy"", 1995, 19th Ed., Mack Printing Company, Easton.;;Gessi, et al., ""The A3 adenosine receptor: An enigmatic player in cell biology"", Pharmacol, Therapeut. 2008, 117, 123-40.;;Givertz, et al., ""The Effects of KW-3902, an Adenosine A1-Receptor Antagonist, on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance"", J. Am. Coll. Cardiol. 2007, 50, 1551-60.;;Gottlieb, ""Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure"", Drugs 2001, 61, 1387-93.;;Greene, et al., ""Protective Groups in Organic Synthesis"", 1999, 3rd Ed., Wiley Interscience, New York.;;Happe, et al., ""Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome"", Neuropsychobiology 2003, 48, 82-6.;;Hasko, et al., ""A2B adenosine receptors in immunity and inflammation"", Trends in Immunol. 2009, 30, 263-70.;;Hodgson, et al., ""Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2, 4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine in Rodent Models of Movement Disorders and Depression"", J. Pharmacol. Exp. Ther. 2009, 330, 294-303.;;Jacobson, et al. ""Adenosine receptors as therapeutic targets"", Nature Reviews Drug Discovery 2006, 5, 247-64.;;Jenner, ""Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments"", J. Neurol, 2000, 247, 1143-50.;;Langer, ""New Methods of Drug Delivery"", Science 1990, 249, 1527.;;Lu, et als.""New Heterocycles Forming Reactions of Acyl Thioformanilides"", Org. Prep. Proced. Int. 1992, 24, 358-62.;;Magano, et al., ""2-(Diethylamino)ethanethiol, a New Reagent for the Odorless Deprotection of Aromatic Methyl Ethers"", J. Org. Chem. 2006, 71, 7103-5.;;Mahajam, et al., ""Synthesis of 3-amino-5-substituted phenylamino-6-phenyl-1, 2, 4-triazines"", Youji Huaxue 1992, 12, 605-7.;;Mallikarjuna, et al., ""Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines"", J. Zhejian Univ. Sci. B 2007, 8, 526-32.;;March, ""Advanced Organic Chemistry"" 1992, 4th Ed., Wiley Interscience, New York, p. 131-133.;;Mcomie, ""Protective Groups in Organic Chemistry"", 1973, Plenum Press, New York.;;Mihara, et al., ""Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of Parkinson's Disease and Cognition"", J. Pharmacol. Exp. Ther. 2007, 323-708-19.;;Murphy, et al., ""One-Pot Synthesis of Arylboronic Acids and Aryl Trifluoroborates by Ir-Catalyzed Borylation of Arenes"", Org. Lett. 2007, 9, 757-60.;;Norton, et al., ""Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart"", Am. J. Physiol. 1999, 276, H341-9.;;Popoli, et al., ""Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum"", J. Neurosci. 2002, 22, 1967-75.;;Quach, et al., ""Ligand- and Base-Free Copper(II)-Catalyzed C-N Bond Formation: Cross-Coupling Reactions of Organoboron Compounds with Aliphatic Amines and Anilines"", Org. Lett. 2003, 5, 4397-400.;;Ryu, et al., ""Phase-Vanishing Reactions that Use Fluorous Media as a Phase Screen. Facile, Controlled Bromination of Alkenes by Dibromine and Dealkylation of Aromatic Ethers by Boron Tribromide"", J. Am. Chem. Soc. 2002, 124, 12946-7.;;Satoh, ""Activation of Adenosine A1-Receptor Pathway Induces Edema Formation in the Pancreas of Rats"", Gastroenterol, 2000, 119, 829-36.;;Sharma, et al., ""Synthesis of Benzo [5, 6] Cyclohept [1, 2, 3, ij] Isoquinolines as Rigid Congeners of Tetrahydropapaveroline"", Heterocycles 1982, 19, 1895-8.;;Stone, et al., ""Neuroprotection by A2A Receptor Antagonists"", Drug Dev. Res. 2001, 52, 323-30.;;Tuite, et al., ""Recent developments in the pharmacological treatment of Parkinson's disease"", J. Expert Opin. Investig. Drugs 2003, 12, 1335-52.;;Wilson, ""Adenosine receptors and asthma in humans"", Brit. J. Pharmacol. 2008, 155, 475-86.;;Wolfe, et al., ""Palladium-Catalyzed Amination of Aryl Halides and Aryl Triflates: N-Hexyl-2-Methyl-4-Methoxyaniline and N-Methyl-N-(4-Chlorophenyl) Aniline"", Orgn. Synth., Coll. vol. 10 2004, 10, 423.;;Zhou, et al., ""Adenosine signaling and the regulation of chronic lung disease"", Pharmacol. Therapeut. 2009, 123, 105-16.;;Zou, et al., ""Study on the syntheses of new 1-o-chlorobenzoyl-3(5'-substituted phenylamino-6'-phenyl)-1', 2', 4'-triazinyl ureas"", Chinese J. Chem. 1998, 16, 58-64.",ACTIVE
12,US,A1,US 2019/0047978 A1,046-573-956-741-493,2019-02-14,2019,US 201816161409 A,2018-10-16,US 201816161409 A;;US 201615344048 A;;US 201514976738 A;;US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-13),https://lens.org/046-573-956-741-493,Patent Application,yes,0,2,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04;;A61K31/4427;;A61K31/506;;A61K31/53;;A61K31/5355;;A61K31/5377;;A61K31/5386;;C07D253/07;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D413/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D487/04,,2,0,,,"Wolff Manfred E. ""Burger's Medicinal Chemistry, 5ed, Part 1"", John Wiley & Sons, 1995, pages 975-977.;;Banker, G.S. et al, ""Modern Pharmaceutices, 3ed."", Marcel Dekker, New York. 1996, pages 451 and 596.",ACTIVE
13,SG,A1,SG 183146 A1,047-900-812-592-144,2012-09-27,2012,SG 2012057436 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/047-900-812-592-144,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,,,0,0,,,,PENDING
14,RS,B1,RS 54897 B1,180-953-190-118-114,2016-10-31,2016,RS P20160454 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W;;EP 11704571 A,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","Jedinjenje, naznačeno time, što ima formulu Iyd,u kojoj:B predstavlja CyBB ili HetBB;CyBB predstavlja fenil opciono supstituisan sa jednim ili više R4c supstituenata;HetBB predstavlja 6-članu aromatsku heterocikličku grupu koja sadrži jedan ili više N atoma, pri čemu je pomenuta HetBB grupa opciono supstituisana sa jednim ili više R4d supstituenata;R4b, R4b', R4c i R4d predstavljaju, nezavisno i uvek kada su prisutni,(a) halo,(b) CN,(c) C1-12 alkil, C2-12 alkenil, C2-12 alkinil, pri čemu su poslednje tri grupe opciono supstituisane sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila (pri čemu su poslednje tri grupe opciono supstituisane sa jendim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi), OR5a, S(O)qR5b, S(O)2N(R5c)(R5d), N(R5e)S(O)2R5f, N(R5g)(R5h), B1-C(G1)-B2-R5i, arila iHet1,(d) Cy3, koja je opciono supstituisana sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila (pri čemu su poslednje tri grupe opciono supstituisane sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi), OR6a, S(O)qR6b, S(O)2N(R6c)(R6d), N(R6e)S(O)2R6f, N(R6g)(R6h), B3-C(G1)-B4-R6i, arila i Het2,(e) Heta, koji je opciono supstituisan da jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila (pri čemu su poslednje tri grupe opciono supstituisane sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi), OR7a, S(O)qR7b, S(O)2N(R7c)(R7d), N(R7e)S(O)2R7f, N(R7g)(R7h), B5-C(G1)-B6-R7i, arila i Het3,(f) OR8,(g) S(O)rR9a,(h) S(O)2N(R9b)(R9c),(i) N(R9d)S(O)2R9e,j) N(R9f)(R9g),(k) B7-C(G')-B8-R9h,(l) =O,(m) =S,rr2 je broj od 0 do 2;ss i tt nezavisno su, uvek kada su prisutni, 0 ili 1, pod uslovom da ss i tt nisu oba 0;L1 i L2 oba predstavljaju direktne veze;G1 predstavlja, nezavisno i uvek kada je prisutan, O, S ili NR5j;R8 predstavlja, nezavisno i uvek kada je prisutan, H,Cy3, Heta, arila, C1-8 alkil, C2-8 alkenil, C2-8 alkinil, C3-8 cikloalkil, pri čemu sedam poslednjih grupa je opciono supstituisano sa jednim ili više supstituenata izabranih iz halo, -CN, C3-6 cikloalkila, arila, Het4, -C(O)OR10, -C(O)Rn, -C(O)N(RN1)(RN2), S(O)rR9aa, S(O)2N(R9ba)(R9ca), N(R9da)S(O)2R9ea i N(R9fa)(R9ga);Cy3 predstavlja, nezavisno i uvek kada je prisutan, 3- do 6-člani aromatski, potpuno zasićeni ili delomično nezasićeni karbociklički prsten;Heta predstavlja, nezavisno i uvek kada je prisutan, 3- do 6-člani heterociklički prsten koji je aromatski, potpuno zasićen ili delomično nezasićen i koji sadrži jedan ili više heteroatoma izabranih iz O, S i N;R10 i R11 nezavisno predstavljaju(a) H,(b) C1-6 alkil opciono supstituisan sa jednim ili više supstituenata izabranih iz halo, arila, -N(RN3)(RN4) i -ORa,(c) aril ili(d) C3-7 cikloalkil (grupa koja je opciono supstituisana sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi);B1 do B8 nezavisno predstavljaju, uvek kada su prisutni, direktnu vezu, O, S ili N(RN3);svaki arila nezavisno predstavlja C6-14 karbocikličku aromatsku grupu koja sadrži jedan, dva ili tri prstena;svaki aril nezavisno predstavlja C6-14 karbocikličku aromatsku grupu koja sadrži jedan, dva ili tri prstena i može da bude supstituisana sa jednim ili više supstituenata izabranihizhalo,C1-6 alkila, pri čemu ova poslednja grupa je opciono supstituisana sa jednim ili višesupstituenata izabranih iz halo, -N(RN4)(RN5) i -ORa, i -ORa;Het1 do Het4 nezavisno predstavljaju 4- do 14-člane heterocikličke grupe koja sadrže jedan ili više heteroatoma izabranih iz O, S i N, pri čemu pomenute heterocikličke grupe mogu da sadrže jedan, dva ili tri prstena i mogu da budu supstituisane sa jednim ili više supstituenata izabranih iz halo,C1-6 alkila, pri čemu ova poslednja grupa je opciono supstituisana sa jednim ili više supstituenata izabranih iz halo, -N(RN6)(RN7) i -ORa, i -ORa;RN1 do RN7 nezavisno predstavljaju H,C1-6 alkil ili C3-6 cikloalkil, pri čemu poslednje dve grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz halo i -ORa;Ra predstavlja, nezavisno i uvek kada je prisutan,(a) H;(b) C1-12 alkil, C2-12 alkenil, C2-12 alkinil, C3-12 cikloalkil, C4-12 cikloalkenil, pri čemu je pet poslednjih grupa opciono supstituisano sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C3-8 cikloalkila (pri čemu poslednje četiri grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi), OR12a, S(O)qR12b, S(O)2N(R12c)(R12d), N(R12e)S(O)2R12f, N(R12g)(R12h), B9-C(G2)-B10-R12i, arila1' i Hetb, i pri čemu C3-12 cikloalkil ili C4-12 cikloalkenil mogu dodatno da budu supstituisani sa =O,(c) S(O)rR13a,(d) S(O)2N(R13b)(R13c) ili(f) C(O)-B11-R13d;R5a do R5J, R6a do R6i, R7a do R7i, R9a do R9h, R9aa do R99a, R12a do R12i i R13a do R13d nezavisno predstavljaju, uvek kada su prisutni,(a) H,(b) C1-10 alkil, C2-10 alkenil, C2-10 alkinil, pri čemu poslednje tri grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C3-6 cikloalkila (pri čemu poslednje tri grupe su opciono supstituisane sajednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi), OR5aa, S(O)qR5ab, S(O)2N(R5ac)(R5ad), N(R5ae)S(O1)2R5af, N(R5ag)(R5ah), B12-C(G2)-B13-R5ai, arila1 i Hetc;(c) C3-10 cikloalkil, ili C4-10 cikloalkenil (pri čemu poslednje dve grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz halo, OH, =O, C1-6 alkila i C1-6 alkoksi),(d) Hetd;G2 predstavlja, nezavisno i uvek kada je prisutan, O, S, ili NR5aj;R5aa do R5aj nezavisno predstavljaju, uvek kada su prisutni,(a) H,(b) C1-4 alkil, C2-4 alkenil, C2-4 alkinil, pri čemu poslednje tri grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-4 alkila, C2-4 alkenila, C2-4 alkinila (pri čemu poslednje tri grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi),(c) C3-6 cikloalkil, ili C4-6 cikloalkenil (pri čemu poslednje dve grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz halo, OH, =O, C1-4 alkila i C1-4 alkoksi),(d) Hete,ili R5ag i R5ah mogu da predstavljaju, zajedno sa atomom azota na kojeg su spojeni, 3-do 10-člani heterociklički prsten koji može da bude aromatski, potpuno zasićen ili delomično nezasićen i koji dodatno sadrži jedan ili više heteroatoma izabranih iz O, S i N, pri čemu pomenuti heterociklički prsten je opciono supstituisan sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila (pri čemu poslednje tri grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi);B9 do B13 nezavisno predstavljaju direktnu vezu, O, S ili N(RN8);aril1 predstavlja, nezavisno i uvek kada je prisutan, C6-10 karbocikličku aromatsku grupu koja može da sadrži jedan ili dva prstena i može da bude supstituisana sa jednim ili više supstituenata izabranih iz halo,C1-6 alkila, pri čemu ova poslednja grupa je opciono supstituisana sa jednim ili više supstituenata izabranih iz halo, -N(RN10)(RN11) i C1-6 alkoksi (pri čemu ovaj poslednji supstituent je opciono supstituisan sa jednim ili više halo atoma), i C1-6 alkoksi (pri čemu je ovaj poslednji supstituent opciono supstituisan sa jednim ili više halo atoma);RN8, RN10 i RN11 nezavisno predstavljaju H,C1-6 alkil ili C3-6 cikloalkil, pri čemu poslednje dve grupe su opciono supstituisane sa jednim ili više halo atoma;Hetb predstavlja 5- ili 6-člani prsten koji može da bude aromatski, potpuno zasićen ili delomično nezasićen i koji sadrži jedan ili više heteroatoma izabranih iz O, S i N, pri čemu pomenuta heterociklička grupa može da bude supstituisana sa jednim ili više supstituenata izabranih iz halo, =O i C1-6 alkila;Hetc do Hef nezavisno predstavljaju 3- do 6-člani heterociklički prsten koji može da bude aromatski, potpuno zasićen ili delomično nezasićen i koji sadrži jedan ili više heteroatoma izabranih iz O, S i N, pri čemu pomenute grupe Hef do Hef su opciono supstituisane sa jednim ili više supstituenata izabranih iz halo, nitro, CN, C1-6 alkila, C2-6 alkenila, C2-6 alkinila (pri čemu poslednje tri grupe su opciono supstituisane sa jednim ili više supstituenata izabranih iz OH, =O, halo, C1-4 alkila i C1-4 alkoksi);q i r nezavisno su, uvek kada su prisutni, 0, 1 ili 2; a,osim ako je drugačije specifikovano, alkil, alkenil, alkinil, cikloalkil i alkilni deo alkoksi grupa mogu da budu supstituisani sa jednim ili više halo atoma;ili neka njegova farmaceutski prihvatljiva so ili solvat.Prijava sadrži još 20 patentnih zahteva.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/180-953-190-118-114,Granted Patent,no,0,0,1,46,0,,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
15,EP,B1,EP 2531492 B1,101-690-870-416-513,2016-04-13,2016,EP 11704571 A,2011-02-07,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/101-690-870-416-513,Granted Patent,yes,4,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,1,0,,,"DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002635106, retrieved from STN Database accession no. 2007:915510 & B.P. MALLIKARJUNA ET AL: JOURNAL OF ZHEJIANG UNIVERSITY, SCIENCE, B, vol. 8, no. 7, 2007, pages 526-532, ISSN: 1673-1581 cited in the application",ACTIVE
16,WO,A1,WO 2011/095625 A1,034-298-249-775-804,2011-08-11,2011,EP 2011051755 W,2011-02-07,US 30206010 P;;US 38176410 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 - A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/034-298-249-775-804,Patent Application,yes,25,54,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,47,31,007-825-957-373-93X;;023-103-617-449-665;;048-989-499-244-089;;128-158-072-964-733;;089-996-350-178-258;;001-392-130-374-249;;057-393-239-160-275;;031-206-250-281-385;;049-984-615-855-375;;094-203-655-035-520;;096-086-179-687-335;;149-788-858-304-284;;117-852-382-648-315;;086-152-334-791-678;;015-651-686-389-616;;020-742-492-212-69X;;028-936-953-315-808;;015-651-686-389-616;;007-035-561-306-128;;038-312-590-427-698;;042-838-227-952-202;;116-389-116-814-538;;002-527-671-094-903;;199-633-235-897-05X;;045-149-256-448-908;;043-181-134-051-352;;136-814-904-308-708;;002-261-516-474-310;;085-318-051-202-184;;008-392-397-583-861;;099-808-125-101-096,10.1152/ajpheart.1999.276.2.h341;;9950832;;10.1152/ajpheart.1999.276.3.h1113;;10070100;;10.2165/00003495-200161100-00002;;11558828;;9443164;;18537674;;pmc2423946;;10.2174/138161208784480090;;10.1517/13543784.12.8.1335;;12882620;;10.1517/eoid.12.8.1335.21771;;11880527;;pmc6758877;;10.1523/jneurosci.22-05-01967.2002;;14504416;;10.1159/000072882;;16871530;;10.1002/art.21974;;10.1002/ddr.1130;;11283304;;10.1146/annurev.neuro.24.1.31;;pmc3463109;;10.1038/nrd1983;;16518376;;17684118;;10.1124/jpet.107.121962;;10.1038/bjp.2008.361;;pmc2579661;;18852693;;10.1016/j.jacc.2007.07.019;;17936154;;19426761;;10.1016/j.pharmthera.2009.04.003;;pmc2743314;;9732378;;10.1016/j.jacc.2007.07.019;;17936154;;10982777;;10.1053/gast.2000.16502;;18029023;;10.1016/j.pharmthera.2007.09.002;;17674488;;10.1631/jzus.2007.b0526;;pmc1906601;;10.1002/jps.2600670554;;205646;;10.1080/00304949209355903;;10.3987/r-1982-10-1865;;2218494;;10.1126/science.2218494;;10.1021/ol035681s.s001;;10.1021/ol035681s;;14602009;;10.1021/ja027965y;;12405811;;10.1021/jo0611059.s001;;16930076;;10.1021/jo0611059;;15132540;;10.1021/jo035886e;;17274623;;10.1021/ol062903o;;10.1021/ol062903o.s001;;10.1124/jpet.108.149617;;19332567,"DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002635106, retrieved from STN Database accession no. 2007:915510;;CHEMICAL & ENGINEERING NEWS, vol. 83, no. 25, 2005;;NORTON ET AL., AM J PHYSIOL., vol. 276, 1999, pages H341 - 9;;BOLLI, AM J PHYSIOL., vol. 276, 1999, pages H1113 - 6;;COSTELLO-BOERRIGTER ET AL., MED CLIN NORTH AM., vol. 87, no. 2, March 2003 (2003-03-01), pages 475 - 91;;GOTTLIEB, DRUGS, vol. 61, no. 10, 2001, pages 1387 - 93;;FEOKTISTOV ET AL., PHARMACOL. REV., vol. 49, 1997, pages 381 - 402;;CUNHA ET AL., CURR PHARM DES., vol. 14, no. 15, 2008, pages 1512 - 1524;;TUITE P ET AL., J. EXPERT OPIN. INVESTIG. DRUGS., vol. 12, 2003, pages 1335 - 52;;POPOLI P. ET AL., J NEUROSCI., vol. 22, 2002, pages 1967 - 75;;DALL'LGNA ET AL., EXPERIMENTAL NEUROLOGY, 2007, pages 241 - 245;;JENNER P., J NEUROL., vol. 247, no. 2, 2000, pages 1143 - 50;;HAPPE S ET AL., NEUROPSYCHOBIOLOGY, vol. 48, 2003, pages 82 - 6;;CHAN ET AL., ARTHRITIS & RHEUMATISM, vol. 54, no. 8, 2006, pages 2632 - 2642;;STONE TW. ET AL., DRAG. DEV. RES., vol. 52, 2001, pages 323 - 330;;DUNWIDDIE TV ET AL., ANN. REV. NEUROSCI., vol. 24, 2001, pages 31 - 55;;KUROKOWA ET AL., PROGRAM NO. 714.4/B101. 2009 NEUROSCIENCE MEETING PLANNER, 2009;;NATURE REVIEWS DRUG DISCOVERY, vol. 5, 2006, pages 247 - 264;;JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 323, no. 2, 2007, pages 708 - 719;;BRITISH JOURNAL OF PHARMACOLOGY, vol. 155, 2008, pages 475 - 486;;JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 50, no. 16, 2007, pages 1551 - 1560;;PHARMACOLOGY AND THERAPEUTICS, vol. 123, 2009, pages 105 - 116;;GELLAI ET AL., J PHARMACOL EXP THER, vol. 286, 1998, pages 1191 - 1196;;J AM COLL CARDIOL, vol. 50, 2007, pages 1551 - 1560;;SATOH ET AL., GASTROENTEROL, vol. 119, no. 3, 2000, pages 829 - 36;;GESSI S ET AL., PHARMACOL. THER., vol. 117, no. 1, 2008, pages 123 - 140;;MALLIKARJUNA ET AL., J ZHEJIAN UNIV SCI B, vol. 8, no. 7, 2007, pages 526 - 532;;DAVIDSON ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 67, no. 5, 1978, pages 737 - 739;;EID ET AL., INDIAN JOURNAL OF CHEMISTRY, vol. 29B, no. 5, 1990, pages 435 - 439;;ZOU ET AL., CHINESE JOURNAL OF CHEMISTRY, vol. 16, no. 1, 1998, pages 58 - 64;;LU ET AL., YOUJI HUAXUE, vol. 12, no. 6, 1992, pages 605 - 607;;LU ET AL., ORGANIC PREPARATIONS AND PROCEDURES INTERNATIONAL, vol. 24, no. 3, 1992, pages 358 - 362;;KONNO ET AL., HETEROCYCLES, vol. 19, no. 10, 1982, pages 1865 - 8;;BRYN ET AL.: ""Solid-State Chemistry of Drugs"", 1999, SSCI, INC;;BUNDEGAARD, H.: ""Design of Prodrugs"", 1985, ELSEVIER, pages: 1 - 92;;JERRY MARCH: ""Advanced Organic Chemistry"", 1992, WILEY INTERSCIENCE, pages: 131 - 133;;REMINGTON: ""The Science and Practice of Pharmacy"", 1995, MACK PRINTING COMPANY;;LANGER, SCIENCE, vol. 249, 1990, pages 1527;;QUACH ET AL., ORG. LETT., vol. 5, 2003, pages 4397 - 4400;;WOLFE ET AL., ORG. SYNTH.; COLL., vol. 10, 2004, pages 423;;I. RYU ET AL., J. AM. CHEM. SOC., vol. 124, 2002, pages 12946 - 12947;;J. MAGANO ET AL., J. ORG. CHEM., vol. 71, 2006, pages 7103 - 7105;;S. K. BOOVANAHALLI ET AL., J. ORG. CHEM., vol. 69, 2004, pages 3340 - 3344;;J. M. MURPHY; C. C. TZSCHUCKE; J. F. HARTWIG, ORG. LETT., vol. 9, 2007, pages 757 - 760;;""Protective Groups in Organic Chemistry"", 1973, PLENUM PRESS;;""Protective Groups in Organic Synthesis"", 1999, WILEY-INTERSCIENCE;;HODGSON ET AL., J. PHARMACOL. EXP. THER., vol. 330, 2009, pages 294 - 303",PENDING
17,MX,A,MX 2012009073 A,036-792-838-888-109,2012-12-17,2012,MX 2012009073 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES.","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/036-792-838-888-109,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
18,PT,T,PT 2531492 T,005-317-643-338-556,2016-07-07,2016,PT 11704571 T,2011-02-07,US 30206010 P;;US 38176410 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,MILES STUART CONGREVE;;STEPHEN PHILIPPE ANDREWS;;JONATHAN STEPHEN MASON;;CHRISTINE MARY RICHARDSON;;GILES ALBERT BROWN,,https://lens.org/005-317-643-338-556,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,PENDING
19,PL,T3,PL 2531492 T3,008-234-949-805-386,2016-10-31,2016,PL 11704571 T,2011-02-07,US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/008-234-949-805-386,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,PENDING
20,SI,T1,SI 2531492 T1,107-382-521-411-953,2016-08-31,2016,SI 201130846 A,2011-02-07,US 38176410 P;;US 30206010 P;;EP 2011051755 W;;EP 11704571 A,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/107-382-521-411-953,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/00;;A61K31/00;;C07D401/00;;C07D403/00;;C07D405/00;;C07D413/00;;C07D417/00;;C07D487/00,,0,0,,,,ACTIVE
21,ES,T3,ES 2579949 T3,158-441-545-173-897,2016-08-17,2016,ES 11704571 T,2011-02-07,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"Derivados de 1,2,4-triazin-4-amina","Compuesto de fórmula lyd, en la que: B representa un CyBB o HetBB; CyBB representa fenilo sustituido opcionalmente con uno o más sustituyentes R4c; HetBB representa un grupo heterocíclico aromático de 6 miembros que contiene uno o más átomos de N, y grupo HetBB que está sustituido opcionalmente con uno o más sustituyentes R4d; R4b, R4b', R4c y R4d representan, independientemente en cada aparición, (a) halógeno, (b) CN, (c) alquilo C1-12, alquenilo C2-12, alquinilo C2-12, estando estos últimos tres grupos sustituidos opcionalmente con uno o más sustituyentes seleccionados de halógeno, nitro, CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 (estando estos últimos tres grupos sustituidos opcionalmente con uno o más sustituyentes seleccionados de OH, >=O, halógeno, alquilo C1-4 y alcoxilo C1-4), OR5a, S(O)qR5b, S(O)2N(R5c)(R5d), N(R5e)S(O)2R5f, N(R5g)(R5h), B1-C(G1)-B2-R5i, arilo y Het1, (d) Cy3, grupo Cy3 que está sustituido opcionalmente con uno o más sustituyentes seleccionados de halógeno, nitro, CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 (estando estos últimos tres grupos sustituidos opcionalmente con uno o más sustituyentes seleccionados de OH, >=O, halógeno, alquilo C1-4 y alcoxilo C1-4), OR6a, S(O)qR6b, S(O)2N(R6c)(R6d), N(R6e)S(O)2R6f, N(R6g)(R6h), B3-C(G1)-B4-R6i, arilo y Het2, (e) Heta, grupo Heta que está sustituido opcionalmente con uno o más sustituyentes seleccionados de halógeno, nitro, CN, alquilo C1-6, alquenilo C2-6, alquinilo C2-6 (estando estos últimos tres grupos sustituidos opcionalmente con uno o más sustituyentes seleccionados de OH, >=O, halógeno, alquilo C1-4 y alcoxilo C1-4), OR7a, S(O)qR7b, S(O)2N(R7c)(R7d), N(R7e)S(O)2R7f, N(R7g)(R7h), B5-C(G1)-B6-R7i, arilo y Het3, (f) OR8, (g) S(O)rR9a, (h) S(O)2N(R9b)(R9c), (i) N(R9d)S(O)2R9e, (j) N(R9f)(R9g), (k) B7-C(G1)-B8-R9h, (l) >=O, (m) >=S, rr2 representa de 0 a 2; ss y tt representan independientemente, en cada aparición 0 ó 1, siempre que ss y tt no representen ambos 0; L1 y L2 representan ambos enlaces directos; G1 representa, independientemente en cada aparición, O, S o NR5j; R8 representa, independientemente en cada aparición, H, Cy3, Heta, ariloa, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, estando estos últimos siete grupos sustituidos opcionalmente con uno o más sustituyentes seleccionados de halógeno, -CN, cicloalquilo C3-6, arilo, Het4, -C(O)OR10, -C(O)R11, -C(O)N(RN1)(RN2), S(O)rR9aa, S(O)2N(R9ba)(R9ca), N(R9da)S(O)2R9ea y N(R9fa)(R9ga); Cy3 representa, independientemente en cada aparición, un anillo carbocíclico, totalmente saturado o parcialmente insaturado, aromático, de 3 a 6 miembros; Heta representa, independientemente en cada aparición, un anillo heterocíclico de 3 a 6 miembros que puede ser aromático, totalmente saturado o parcialmente insaturado y que contiene uno o más heteroátomos seleccionados de O, S y N; R10 y R11 representan independientemente (a) H, (b) alquilo C1-6 sustituido opcionalmente con uno o más sustituyentes seleccionados de halógeno, arilo, -N(RN3)(RN4) y -ORa, (c) arilo o (d) cicloalquilo C3-7 (grupo que está sustituido opcionalmente con uno o más sustituyentes seleccionados de OH, >=O, halógeno, alquilo C1-4 y alcoxilo C1-4); B1 a B8 representan independientemente, en cada aparición, un enlace directo, O, S o N(RN3); cada ariloa representa independientemente un grupo aromático carbocíclico C6-14, grupo que puede comprender uno, dos o tres anillos; cada arilo representa independientemente un grupo aromático carbocíclico C6-14, grupo que puede comprender uno, dos o tres anillos y puede estar sustituido con uno o más sustituyentes seleccionados de halógeno, alquilo C1-6, estando este último grupo sustituido opcionalmente con uno o más sustituyentes seleccionados de halógeno, -N(RN4)(RN5) y -ORa, y -ORa; Het1 a Het4 representan independientemente grupos heterocíclicos de 4 a 14 miembros que contienen uno o más heteroátomos seleccionados de O, S y N, grupos heterocíclicos que pueden comprender uno, dos o tres anillos y puede estar sustituido con uno o más sustituyentes seleccionados de halógeno, alquilo C1-6, estando este último grupo sustituido opcionalmente con uno o más sustituyentes seleccionados de halógeno, -N(RN6)(RN7) y -ORa, y -ORa; RN1 a RN7 representan independientemente H, alquilo C1-6 o cicloalquilo C3-6, estando estos últimos dos grupos sustituidos opcionalmente con uno o más sustituyentes seleccionados de halógeno y -ORa;",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/158-441-545-173-897,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
22,AU,A1,AU 2011/212430 A1,187-675-675-480-864,2012-08-23,2012,AU 2011/212430 A,2011-02-07,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"1,2,4-triazine-4-amine derivatives","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A- A or, particularly, the A receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy or Het; Cy represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy group is optionally substituted by one or more R substituents; Het represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy or Het; Cy represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy group is optionally substituted by one or more R substituents; Het represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het group is optionally substituted by one or more R substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/187-675-675-480-864,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
23,HR,T1,HR P20160636 T1,024-745-039-193-768,2016-07-29,2016,HR P20160636 T,2016-06-09,US 30206010 P;;US 38176410 P;;EP 11704571 A;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/024-745-039-193-768,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
24,MY,A,MY 180024 A,089-029-043-643-750,2020-11-19,2020,MY PI2012003522 A,2011-02-07,US 30206010 P;;US 38176410 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A,- A2b or, particularly, the A2. receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA, Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY,,https://lens.org/089-029-043-643-750,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04;;C07D253/07;;C07D401/12,,0,0,,,,ACTIVE
25,DK,T3,DK 2531492 T3,091-421-894-507-210,2016-07-04,2016,DK 11704571 T,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZIN-4-AMINDERIVATER",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/091-421-894-507-210,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
26,AU,B2,AU 2011/212430 B2,150-967-138-402-256,2014-05-29,2014,AU 2011/212430 A,2011-02-07,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"1,2,4-triazine-4-amine derivatives",According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/150-967-138-402-256,Granted Patent,no,1,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
27,CY,T1,CY 1117780 T1,054-883-055-898-876,2017-05-17,2017,CY 161100573 T,2016-06-23,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"ΠΑΡΑΓΩΓΑ 1,2,4-ΤΡΙΑΖΟΝΟ-4-ΑΜΙΝΗΣ","Σύμφωνα με την εφεύρεση παρέχεται μία ένωση του τύπου Α1, η οποία μπορεί να είναι χρήσιμη στην θεραπευτική αντιμετώπιση μίας κατάστασης ή διαταραχής που βελτιώνεται από την αναστολή του υποδοχέα Α1- A2b ή, συγκεκριμένα, του A2a, όπου η ένωση του τύπου Α1 έχει τη δομή, όπου, το Α αντιπροσωπεύει Cy1 ή HetA· το Cy1 αντιπροσωπεύει ένα σύστημα 5- έως 14-μελούς αρωματικού, πλήρως κορεσμένου ή εν μέρει ακόρεστου καρβοκυκλικού δακτυλίου που περιλαμβάνει ένα, δύο ή τρεις δακτυλίους, η οποία Cy1 ομάδα είναι προαιρετικά υποκατεστημένη από έναν ή περισσότερους R4a υποκατάστατες· το HetA αντιπροσωπεύει μία 5- έως 14-μελή ετεροκυκλική ομάδα που μπορεί να είναι αρωματική, πλήρως κορεσμένη ή εν μέρει ακόρεστη, και η οποία περιέχει ένα ή περισσότερα ετεροάτομα που επιλέγονται από Ο, S και Ν, η οποία ετεροκυκλική ομάδα μπορεί να περιλαμβάνει έναν, δύο ή τρεις δακτυλίους και η οποία HetA ομάδα είναι προαιρετικά υποκατεστημένη από έναν ή περισσότερους R4b υποκατάστατες· το Β αντιπροσωπεύει ένα Cy2 ή HetB· το Cy2 αντιπροσωπεύει ένα σύστημα 3- έως 10-μελούς αρωματικού, πλήρως κορεσμένου ή εν μέρει ακόρεστου καρβοκυκλικού δακτυλίου που περιλαμβάνει έναν ή δύο δακτυλίους, η οποία Cy2 ομάδα είναι προαιρετικά υποκατεστημένη από έναν ή περισσότερους R4c υποκατάστατες· το HetB αντιπροσωπεύει μία 3- έως 10-μελή ετεροκυκλική ομάδα που μπορεί να είναι αρωματική, πλήρως κορεσμένη ή εν μέρει ακόρεστη, και η οποία περιέχει ένα ή περισσότερα ετεροάτομα που επιλέγονται από Ο, S και Ν, η οποία ετεροκυκλική ομάδα μπορεί να περιλαμβάνει έναν ή δύο δακτυλίους και η οποία HetB ομάδα είναι προαιρετικά υποκατεστημένη από έναν ή περισσότερους R4d υποκατάστατες.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/054-883-055-898-876,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
28,HU,T2,HU E028640 T2,159-231-943-330-692,2016-12-28,2016,HU E11704571 A,2011-02-07,US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/159-231-943-330-692,Amended Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,A61K31/53,,0,0,,,,PENDING
29,CN,A,CN 102822150 A,132-454-566-833-902,2012-12-12,2012,CN 201180017840 A,2011-02-07,EP 2011051755 W;;US 30206010 P;;US 38176410 P,2010-02-05,"1,2,4-triazine-4-amine derivatives","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/132-454-566-833-902,Patent Application,no,2,18,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
30,US,A1,US 2013/0029963 A1,180-146-783-717-832,2013-01-31,2013,US 201113576798 A,2011-02-07,US 201113576798 A;;US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/180-146-783-717-832,Patent Application,yes,0,2,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,A61K31/53;;A61K31/5377;;A61P1/12;;A61P1/16;;A61P3/10;;A61P7/10;;A61P9/04;;A61P13/12;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;C07D253/07;;C07D401/10;;C07D403/10;;C07D405/10;;C07D413/14,514/210.2;;544/182;;514/242;;544/112;;514/236.2,3,1,130-680-203-388-320,10.1038/nbt0394-320,"Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,Volume 1, 1004-101 O, 1996.;;Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p4.;;Dermer et al., Bio/Technology, 1994, 12:320.",ACTIVE
31,EP,A1,EP 2531492 A1,178-077-415-850-404,2012-12-12,2012,EP 11704571 A,2011-02-07,US 38176410 P;;US 30206010 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/178-077-415-850-404,Patent Application,yes,0,1,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
32,US,A1,US 2017/0291888 A1,021-965-663-702-840,2017-10-12,2017,US 201615344048 A,2016-11-04,US 201615344048 A;;US 201514976738 A;;US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 21 , or, particularly, the A 2 , receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/021-965-663-702-840,Patent Application,yes,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04,,0,0,,,,ACTIVE
33,US,B2,US 9249130 B2,074-245-250-566-569,2016-02-02,2016,US 201414322505 A,2014-07-02,US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-triazine-4-amine derivatives","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/074-245-250-566-569,Granted Patent,yes,25,2,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/397;;A61K31/4155;;A61K31/4427;;A61K31/443;;A61K31/506;;A61K31/53;;A61K31/5355;;A61K31/5377;;A61P25/28;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D403/14;;C07D405/04;;C07D405/10;;C07D413/04;;C07D413/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D487/04,,53,39,018-503-924-256-865;;023-103-617-449-665;;173-468-323-248-682;;045-255-739-470-754;;049-984-615-855-375;;049-844-139-775-117;;089-996-350-178-258;;162-922-566-598-984;;116-389-116-814-538;;130-680-203-388-320;;082-786-111-595-062;;096-086-179-687-335;;031-369-160-374-939;;128-158-072-964-733;;028-936-953-315-808;;038-312-590-427-698;;015-651-686-389-616;;048-989-499-244-089;;031-206-250-281-385;;053-688-150-554-166;;099-808-125-101-096;;149-788-858-304-284;;043-050-631-124-639;;045-149-256-448-908;;002-261-516-474-310;;042-838-227-952-202;;117-852-382-648-315;;008-392-397-583-861;;007-825-957-373-93X;;057-393-239-160-275;;043-181-134-051-352;;136-814-904-308-708;;007-035-561-306-128;;167-584-024-775-184;;094-203-655-035-520;;001-392-130-374-249;;086-152-334-791-678;;076-801-301-292-463;;020-742-492-212-69X,pmc3437034;;22961543;;10.1093/brain/aws225;;10.1152/ajpheart.1999.276.3.h1113;;10070100;;10.1007/978-3-540-89615-9_19;;19639295;;10.1002/chin.200437037;;16871530;;10.1002/art.21974;;10.1016/s0025-7125(02)00181-5;;12693735;;18537674;;pmc2423946;;10.2174/138161208784480090;;17007839;;10.1016/j.expneurol.2006.08.008;;10.1002/jps.2600670554;;205646;;10.1038/nbt0394-320;;1795036;;10.1016/s0021-9673(01)88448-x;;11283304;;10.1146/annurev.neuro.24.1.31;;10.1002/chin.199033200;;9443164;;9732378;;18029023;;10.1016/j.pharmthera.2007.09.002;;10.1016/j.jacc.2007.07.019;;17936154;;10.2165/00003495-200161100-00002;;11558828;;14504416;;10.1159/000072882;;pmc2756472;;10.1016/j.it.2009.04.001;;19427267;;10.1124/jpet.108.149617;;19332567;;pmc3463109;;10.1038/nrd1983;;16518376;;10.1007/pl00007760;;10991665;;2218494;;10.1126/science.2218494;;10.1021/jo0611059.s001;;16930076;;10.1021/jo0611059;;17674488;;10.1631/jzus.2007.b0526;;pmc1906601;;17684118;;10.1124/jpet.107.121962;;17274623;;10.1021/ol062903o;;10.1021/ol062903o.s001;;10.1152/ajpheart.1999.276.2.h341;;9950832;;11880527;;pmc6758877;;10.1523/jneurosci.22-05-01967.2002;;10.1021/ol035681s.s001;;10.1021/ol035681s;;14602009;;10.1021/ja027965y;;12405811;;10982777;;10.1053/gast.2000.16502;;10.3987/r-1982-10-1895;;10.1002/ddr.1130;;10.1517/13543784.12.8.1335;;12882620;;10.1517/eoid.12.8.1335.21771;;10.1038/bjp.2008.361;;pmc2579661;;18852693;;10.15227/orgsyn.078.0023;;19426761;;10.1016/j.pharmthera.2009.04.003;;pmc2743314,"Imbrici et al. Frontiers in Genetics 2013, vol. 7, Article 76, pp. 1-19.;;Eijkelkamp et al. Brain 2012, 135; 2585-2612.;;""L-DOPA"", Chem. Eng. News 2005, 83(25) 60.;;2009 Meeting Planner, Society for Neuroscience, Chicago, IL, Program No. 714.4/B101.;;Auchampach, et al., ""Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges"", Am. J. Physiol. 1999, 276, H1113-6.;;Bauer, et al., ""Adenosine Receptor Ligands and PET Imaging of the CNS"", Wilson and Mustafa ""Adenosine Receptors in Health and Disease"", Handbook of Experimental Pharmacology, 2009, Springer, Berlin, p. 617-642.;;Boovanahalli, et al., ""Application of Ionic Liquid Halide Nucleophilicity for the Cleavage of Ethers: A Green Protocol for the Regeneration of Phenols form Ethers"", J. Org. Chem. 2004, 69, 3340-4.;;Bundgaard, ""Design of prodrugs"", 1985, Elsevier, New York, p. 1-92.;;Byrn, et al., ""Solid-State Chemistry of Drugs"", 1999 2nd Ed., SSCI, Inc. of West LaFayette.;;Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-101 O, 1996.;;Chan, et al., ""Adenosine A2A Receptors in Diffuse Dermal Fibrosis"", Arthris Rheum. 2006, 54, 2632-42.;;Costello-Boerrigter, et al., ""Revisiting sale and water retention: new diuretics, aquaretics, and natriuretics"", Med. Clin. North Am. 2003, 87, 475-91.;;Cunha, et al., ""Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders"", Curr. Pharm. Des. 2008, 14, 1512-24.;;Dall'Igna, ""Caffeine and adenosine A2a receptor antagonists prevent beta-amyloid (25-35)-induced cognitive deficits in mice"", Exp. Neurol. 2007, 241-5.;;Davidson, et al., ""Synthesis of as-Triazines as Potential Antiviral Agents"", J Pharm. Sci. 1978, 67, 737-9.;;Dermer et al., Bio/Technology, 1994, 12:320.;;Doig, et al, ""Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine"", J. Chromatogr. 1991, 554, 181-9.;;Dunwiddie, et al., ""The Role and Regulation of Adenosine in the Central Nervous System"", Ann. Rev. Neurosci. 2001, 24, 31-55.;;Eid, et al., ""Reactions of 3-amino/substituted amino-6-benzyl-5-thioxo-and 5-chloro-1, 2, 4-triazines: Synthesis of 3,5-substituted diamino- 1, 2, 4-triazines and 5-amino/substituted amino-8-benzyl-3-thioxo-s-triazolo [4, 3-d] [1, 2, 4] triazines"", in. J. Chem. B 1990, 29B, 435-9.;;Feoktistov, et al., ""Adenosine A2B Receptors"", Pharmacol. Rev. 1997, 49, 381-402.;;Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.;;Gellai, et al., ""CVT-124, a Novel Adenosine A1 Receptor Antagonist with Unique Diuretic Activity"", J. Pharmacol. Exp. Ther. 1998, 286, 1191-96.;;Gennaro, ""Remington, The Science and Practice of Pharmacy"", 1995, 19th Ed., Mack Printing Company, Easton.;;Gessi, et al., ""The A3 adenosine receptor: An enigmatic player in cell biology"", Pharmacol, Therapeut. 2008, 117, 123-40.;;Givertz, et al., ""The Effects of KW-3902, an Adenosine A1-Receptor Antagonist, on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance"", J. Am. Coll. Cardiol. 2007, 50, 1551-60.;;Gottlieb, ""Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure"", Drugs 2001, 61, 1387-93.;;Greene, et al., ""Protective Groups in Organic Synthesis"", 1999, 3rd Ed., Wiley Interscience, New York.;;Happe, et al., ""Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome"", Neuropsychobiology 2003, 48, 82-6.;;Hasko, et al., ""A2B adenosine receptors in immunity and inflammation"", Trends in Immunol. 2009, 30, 263-70.;;Hodgson, et al., ""Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2, 4-DifluorophenyI]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c] pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression"", J. Pharmacol. Exp. Ther. 2009, 330, 294-303.;;Jacobson, et al. ""Adenosine receptors as therapeutic targets"", Nature Reviews Drug Discovery 2006, 5, 247-64.;;Jenner, ""Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments"", J. Neurol, 2000, 247, 1143-50.;;Langer, ""New Methods of Drug Delivery"", Science 1990, 249, 1527.;;Lu, et al.""New Heterocycles Forming Reactions of Acyl Thioformanilides"", Org. Prep. Proced. Int. 1992, 24, 358-62.;;Magano, et al., ""2-(Diethylamino)ethanethiol, a New Reagent for the Odorless Deprotection of Aromatic Methyl Ethers"", J. Org. Chem. 2006, 71, 7103-5.;;Mahajam, et al., ""Synthesis of 3-amino-5-substituted phenylamino-6-phenyl-1, 2, 4-triazines"", Youji Huaxue 1992, 12, 605-7.;;Mallikarjuna, et al., ""Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines"", J. Zhejian Univ. Sci. B 2007, 8, 526-32.;;March, ""Advanced Organic Chemistry"" 1992, 4th Ed., Wiley Interscience, New York, p. 131-133.;;Mcomie, ""Protective Groups in Organic Chemistry"", 1973, Plenum Press, New York.;;Mihara, et al., ""Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of Parkinson's Disease and Cognition"", J. Pharmacol. Exp. Ther. 2007, 323-708-19.;;Murphy, et al., ""One-Pot Synthesis of Arylboronic Acids and Aryl Trifluoroborates by Ir-Catalyzed Borylation of Arenes"", Org. Lett. 2007, 9, 757-60.;;Norton, et al., ""Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart"", Am. J. Physiol 1999, 276, H341-9.;;Popoli, et al., ""Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum"", J. Neurosci. 2002, 22, 1967-75.;;Quach, et al., ""Ligand- and Base-Free Copper(II)-Catalyzed C-N Bond Formation: Cross-Coupling Reactions of Organoboron Compounds with Aliphatic Amines and Anilines"", Org. Lett. 2003, 5, 4397-400.;;Ryu, et al., ""Phase-Vanishing Reactions that Use Fluorous Media as a Phase Screen. Facile, Controlled Bromination of Alkenes by Dibromine and Dealkylation of Aromatic Ethers by Boron Tribromide"", J. Am. Chem. Soc. 2002, 124, 12946-7.;;Satoh, ""Activation of Adenosine A1-Receptor Pathway Induces Edema Formation in the Pancreas of Rats"", Gastroenterol, 2000, 119, 829-36.;;Sharma, et al., ""Synthesis of Benzo [5, 6] Cyclohept [1, 2, 3, ij] Isoquinolines as Rigid Congeners of Tetrahydropapaveroline"", Heterocycles 1982, 19, 1895-8.;;Stone, et al., ""Neuroprotection by A2A Receptor Antagonists"", Drug Dev. Res. 2001, 52, 323-30.;;Tuite, et al., ""Recent developments in the pharmacological treatment of Parkinson's disease"", J. Expert Opin. Investig. Drugs 2003, 12, 1335-52.;;Wilson, ""Adenosine receptors and asthma in humans"", Brit. J. Pharmacol. 2008, 155, 475-86.;;Wolfe, et al., ""Palladium-Catalyzed Amination of Aryl Halides and Aryl Triflates: N-Hexyl-2-Methyl-4-Methoxyaniline and N-Methyl-N-(4-Chlorophenyl) Aniline"", Orgn. Synth., Coll. vol. 10 2004, 10, 423.;;Zhou, et al., ""Adenosine signaling and the regulation of chronic lung disease"", Pharmacol. Therapeut. 2009, 123, 105-16.;;Zou, et al., ""Study on the syntheses of new 1-o-chlorobenzoy1-3(5'-substituted phenylamino-6'-phenyl)-1', 2', 4'- triazinyl ureas"", Chinese J. Chem. 1998, 16, 58-64.",ACTIVE
34,US,A1,US 2015/0005276 A1,187-906-060-151-090,2015-01-01,2015,US 201414322505 A,2014-07-02,US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/187-906-060-151-090,Patent Application,yes,1,1,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D413/14;;C07D253/07;;C07D401/04;;C07D401/14;;C07D405/04;;C07D413/04,514/210.2;;514/242;;514/236.2;;514/230.5,2,1,018-503-924-256-865,pmc3437034;;22961543;;10.1093/brain/aws225,"Imbrici et al. Frontiers in Genetics 2013, Volume 7, Article 76, pages 1-19.;;Eijkelkamp et al. Brain 2012, 135; 2585-2612.",ACTIVE
35,US,B2,US 10112923 B2,117-404-439-450-846,2018-10-30,2018,US 201615344048 A,2016-11-04,US 201615344048 A;;US 201514976738 A;;US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-triazine-4-amine derivatives","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/117-404-439-450-846,Granted Patent,yes,26,16,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04;;A61K31/4427;;A61K31/506;;A61K31/53;;A61K31/5355;;A61K31/5377;;A61K31/5386;;A61P35/00;;C07D253/07;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D413/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D487/04,,53,39,018-503-924-256-865;;066-456-059-551-748;;023-103-617-449-665;;173-468-323-248-682;;045-255-739-470-754;;049-984-615-855-375;;049-844-139-775-117;;089-996-350-178-258;;116-389-116-814-538;;130-680-203-388-320;;082-786-111-595-062;;096-086-179-687-335;;031-369-160-374-939;;128-158-072-964-733;;028-936-953-315-808;;038-312-590-427-698;;015-651-686-389-616;;048-989-499-244-089;;031-206-250-281-385;;053-688-150-554-166;;099-808-125-101-096;;149-788-858-304-284;;043-050-631-124-639;;045-149-256-448-908;;002-261-516-474-310;;042-838-227-952-202;;117-852-382-648-315;;008-392-397-583-861;;007-825-957-373-93X;;057-393-239-160-275;;043-181-134-051-352;;136-814-904-308-708;;007-035-561-306-128;;167-584-024-775-184;;094-203-655-035-520;;001-392-130-374-249;;086-152-334-791-678;;076-801-301-292-463;;020-742-492-212-69X,pmc3437034;;22961543;;10.1093/brain/aws225;;23675382;;pmc3646240;;10.3389/fgene.2013.00076;;10.1152/ajpheart.1999.276.3.h1113;;10070100;;10.1007/978-3-540-89615-9_19;;19639295;;10.1002/chin.200437037;;16871530;;10.1002/art.21974;;10.1016/s0025-7125(02)00181-5;;12693735;;18537674;;pmc2423946;;10.2174/138161208784480090;;10.1002/jps.2600670554;;205646;;10.1038/nbt0394-320;;1795036;;10.1016/s0021-9673(01)88448-x;;11283304;;10.1146/annurev.neuro.24.1.31;;10.1002/chin.199033200;;9443164;;9732378;;18029023;;10.1016/j.pharmthera.2007.09.002;;10.1016/j.jacc.2007.07.019;;17936154;;10.2165/00003495-200161100-00002;;11558828;;14504416;;10.1159/000072882;;pmc2756472;;10.1016/j.it.2009.04.001;;19427267;;10.1124/jpet.108.149617;;19332567;;pmc3463109;;10.1038/nrd1983;;16518376;;10.1007/pl00007760;;10991665;;2218494;;10.1126/science.2218494;;10.1021/jo0611059.s001;;16930076;;10.1021/jo0611059;;17674488;;10.1631/jzus.2007.b0526;;pmc1906601;;17684118;;10.1124/jpet.107.121962;;17274623;;10.1021/ol062903o;;10.1021/ol062903o.s001;;10.1152/ajpheart.1999.276.2.h341;;9950832;;11880527;;pmc6758877;;10.1523/jneurosci.22-05-01967.2002;;10.1021/ol035681s.s001;;10.1021/ol035681s;;14602009;;10.1021/ja027965y;;12405811;;10982777;;10.1053/gast.2000.16502;;10.3987/r-1982-10-1895;;10.1002/ddr.1130;;10.1517/13543784.12.8.1335;;12882620;;10.1517/eoid.12.8.1335.21771;;10.1038/bjp.2008.361;;pmc2579661;;18852693;;10.15227/orgsyn.078.0023;;19426761;;10.1016/j.pharmthera.2009.04.003;;pmc2743314,"Zou, et al., “Study on the syntheses of new 1-o-chlorobenzoyl-3(5′-substituted phenylamino-6′-phenyl)-1′, 2′, 4′-triazinyl ureas”, Chinese J. Chem. 1998, 16, 58-64.;;Eijkelkamp et al., “Neurological perspectives on voltage-gated sodium channels” Brain J. of Neurology: 135: 2585-2612, 2012.;;Imbrici et al., “Major channels involved in neuropsychiatric disorders and therapeutic perspectives” Frontiers in Genetics, vol. 4(Article 76):1-19, 2013.;;“L-DOPA”, Chem. Eng. News 2005, 83(25) 60.;;2009 Meeting Planner, Society for Neuroscience, Chicago, IL, Program No. 714.4/B101.;;Auchampach, et al., “Adenosine receptor subtypes in the heart: therapeutic opportunities and challenges”, Am. J. Physiol. 1999, 276, H1113-6.;;Bauer, et al., “Adenosine Receptor Ligands and PET Imaging of the CNS”, Wilson and Mustafa “Adenosine Receptors in Health and Disease”, Handbook of Experimental Pharmacology, 2009, Springer, Berlin, p. 617-42.;;Boovanahalli, et al., “Application of Ionic Liquid Halide Nucleophilicity for the Cleavage of Ethers: A Green Protocol for the Regeneration of Phenols form Ethers”, J. Org. Chem. 2004, 69, 3340-4.;;Bundgaard, “Design of prodrugs”, 1985, Elsevier, New York, p. 1-92.;;Byrn, et al., “Solid-State Chemistry of Drugs”, 1999 2nd Ed., SSCI, Inc. of West LaFayette.;;Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-101 O, 1996.;;Chan, et al., “Adenosine A2A Receptors in Diffuse Dermal Fibrosis”, Arthris Rheum. 2006, 54, 2632-42.;;Costello-Boerrigter, et al., “Revisiting sale and water retention: new diuretics, aquaretics, and natriuretics”, Med. Clin. North Am. 2003, 87, 475-91.;;Cunha, et al., “Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders”, Curr. Pharm. Des. 2008, 14, 1512-24.;;Dall'Igna, “Caffeine and adenosine A2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in nice”, Exp. Neurol. 2007, 241-5.;;Davidson, et al., “Synthesis of as-Triazines as Potential Antiviral Agents”, J Pharm. Sci. 1978, 67, 737-9.;;Dermer et al., Bio/Technology, 1994, 12:320.;;Doig, et al, “Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine”, J. Chromatogr. 1991, 554, 181-9.;;Dunwiddie, et al., “The Role and Regulation of Adenosine in the Central Nervous System”, Ann. Rev. Neurosci. 2001, 24, 31-55.;;Eid, et al., “Reactions of 3-amino/substituted amino-6-benzyl-5-thioxo-and 5-chloro-1, 2, 4-triazines: Synthesis of 3,5-substituted diamino-1, 2, 4-triazines and 5-amino/substituted amino-8-benzyl-3-thioxo-s-triazolo [4, 3-d] [1, 2, 4] triazines”, In. J. Chem. B 1990, 29B, 435-9.;;Feoktistov, et al., “Adenosine A2B Receptors”, Pharmacol. Rev. 1997, 49, 381-402.;;Freshney et al.,Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4.;;Gellai, et al., “CVT-124, a Novel Adenosine A1 Receptor Antagonist with Unique Diuretic Activity”, J. Pharmacol. Exp. Ther. 1998, 286, 1191-96.;;Gennaro, “Remington, The Science and Practice of Pharmacy”, 1995, 19th Ed., Mack Printing Company, Easton.;;Gessi, et al., “The A3 adenosine receptor an enigmatic player in cell biology”, Pharmacol, Therapeut. 2008, 117, 123-40.;;Givertz, et al., “The Effects of KW-3902, an Adenosine A1-Receptor Antagonist, on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance”, J. Am. Coll. Cardiol. 2007, 50, 1551-60.;;Gottlieb, “Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure”, Drugs 2001, 61, 1387-93.;;Greene, et al., “Protective Groups in Organic Synthesis”, 1999, 3rd Ed., Wiley Interscience, New York.;;Happe, et al., “Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs Syndrome”, Neuropsychobiology 2003, 48, 82-6.;;Hasko, et al., “A2B adenosine receptors in immunity and inflammation”, Trends in Immunol. 2009, 30, 263-70.;;Hodgson, et al., “Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2, 4-Difluorophenyl]-1-piperazinyl]-ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression”, J. Pharmacol. Exp. Ther. 2009, 330, 294-303.;;Jacobson, et al. “Adenosine receptors as therapeutic targets”, Nature Reviews Drug Discovery 2006, 5, 247-64.;;Jenner, “Pathophysiology and biochemistry of dyskinesia: clues for the development of non-dopaminergic treatments”, J. Neurol, 2000, 247, 1143-50.;;Langer, “New Methods of Drug Delivery”, Science 1990, 249, 1527.;;Lu, et als. “New Heterocycles Forming Reactions of Acyl Thioformanilides”, Org. Prep. Proced. Int. 1992, 24, 358-62.;;Magano, et al., “2-(Diethylamino)ethanethiol, a New Reagent for the Odorless Deprotection of Aromatic Methyl Ethers”, J. Org. Chem. 2006, 71, 7103-5.;;Mahajam, et al., “Synthesis of 3-amino-5-substituted phenylamino-6-phenyl-1, 2, 4-triazines”, Youji Huaxue 1992, 12, 605-7.;;Mallikarjuna, et al., “Synthesis and anticonvulsant activity of some potent 5,6-bis aryl 1,2,4-triazines”, J. Zhejian Univ. Sci. B 2007, 8, 526-32.;;March, “Advanced Organic Chemistry” 1992, 4th Ed., Wiley Interscience, New York, p. 131-133.;;Mcomie, “Protective Groups in Organic Chemistry”, 1973, Plenum Press, New York.;;Mihara, et al., “Pharmacological Characterization of a Novel, Potent Adenosine A1 and A2A Receptor Dual Antagonist, 5-[5-Amino-3(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in Models of Parkinson's Disease and Cognition”, J. Pharmacol. Exp. Ther. 2007, 323-708-19.;;Murphy, et al., “One-Pot Synthesis of Arylboronic Acids and Aryl Trifluoroborates by Ir-Catalyzed Borylation of Arenes”, Org. Lett. 2007, 9, 757-60.;;Norton, et al., “Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart”, Am. J. Physiol. 1999, 276, H341-9.;;Popoli, et al., “Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum”, J. Neurosci. 2002, 22, 1967-75.;;Quach, et al., “Ligand- and Base-Free Copper(II)-Catalyzed C—N Bond Formation: Cross-Coupling Reactions of Organoboron Compounds with Aliphatic Amines and Anilines”, Org. Lett. 2003, 5, 4397-400.;;Ryu, et al., “Phase-Vanishing Reactions that Use Fluorous Media as a Phase Screen. Facile, Controlled Bromination of Alkenes by Dibromine and Dealkylation of Aromatic Ethers by Boron Tribromide”, J. Am. Chem. Soc. 2002, 124, 12946-7.;;Satoh, “Activation of Adenosine A1-Receptor Pathway Induces Edema Formation in the Pancreas of Rats”, Gastroenterol, 2000, 119, 829-36.;;Sharma, et al., “Synthesis of Benzo [5, 6] Cyclohept [1, 2, 3, ij] Isoquinolines as Rigid Congeners of Tetrahydropapaveroline”, Heterocycles 1982, 19, 1895-8.;;Stone, et al., “Neuroprotection by A2A Receptor Antagonists”, Drug Dev. Res. 2001, 52, 323-30.;;Tuite, et al., “Recent developments in the pharmacological treatment of Parkinson's disease”, J. Expert Opin. Investig. Drugs 2003, 12, 1335-52.;;Wilson, “Adenosine receptors and asthma in humans”, Brit. J. Pharmacol. 2008, 155, 475-86.;;Wolfe, et al., “Palladium-Catalyzed Amination of Aryl Halides and Aryl Triflates: N-Hexyl-2-Methyl-4-Methoxyaniline and N-Methyl-N-(4-Chlorophenyl) Aniline”, Orgn. Synth., Coll. vol. 10 2004, 10, 423.;;Zhou et al., “Adenosine signaling and the regulation of chronic lung disease”, Pharmacol. Therapeut. 2009, 123, 105-16.",ACTIVE
36,MX,B,MX 352415 B,156-990-731-057-127,2017-11-22,2017,MX 2012009073 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES.","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD STAR,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/156-990-731-057-127,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
37,CA,A1,CA 2789279 A1,024-167-206-679-385,2011-08-11,2011,CA 2789279 A,2011-02-07,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A1- A2b or, particularly, the A2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy1 or HetA; Cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy1 group is optionally substituted by one or more R4a substituents; HetA represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy2 or HetB; Cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy2 group is optionally substituted by one or more R4c substituents; HetB represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which HetB group is optionally substituted by one or more R4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/024-167-206-679-385,Patent Application,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
38,ZA,B,ZA 201205788 B,041-815-158-059-139,2015-05-27,2015,ZA 201205788 A,2012-08-01,US 30206010 P;;US 38176410 P;;EP 2011051755 W,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/041-815-158-059-139,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,A61K/;;C07D/,,0,0,,,,ACTIVE
39,US,A1,US 2023/0021177 A1,074-429-153-505-947,2023-01-19,2023,US 202117239137 A,2021-04-23,US 202117239137 A;;US 201816161409 A;;US 201615344048 A;;US 201514976738 A;;US 201414322505 A;;US 201213576798 A;;EP 2011051755 W;;US 38176410 P;;US 30206010 P,2010-02-05,"1,2,4-TRIAZINE-4-AMINE DERIVATIVES","According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A 1 -A 2b or, particularly, the A 2a receptor wherein the compound of formula A1 has the structure, wherein, A represents Cy 1 or Het A ; Cy 1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one, two or three rings, which Cy 1 group is optionally substituted by one or more R 4a substituents; Het A represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more hetermatoms selected from O, S and N, which heterocyclic group may comprise one, two or three rings and which HetA group is optionally substituted by one or more R4b substituents; B represents a Cy 2 or Het B ; Cy 2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which Cy 2 group is optionally substituted by one or more R 4c substituents; Het B represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from O, S and N, which heterocyclic group may comprise one or two rings and which Het B group is optionally substituted by one or more R 4d substituents.",HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,HEPTARES THERAPEUTICS LIMITED (2013-07-26);;BIOFOCUS DPI LTD (2013-08-02),https://lens.org/074-429-153-505-947,Patent Application,yes,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D401/04;;A61K31/4427;;A61K31/506;;A61K31/53;;A61K31/5355;;A61K31/5377;;A61K31/5386;;C07D253/07;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D413/14;;C07D417/04;;C07D417/12;;C07D417/14;;C07D487/04,,0,0,,,,PENDING
40,CN,B,CN 102822150 B,170-924-817-408-209,2014-12-03,2014,CN 201180017840 A,2011-02-07,EP 2011051755 W;;US 30206010 P;;US 38176410 P,2010-02-05,"1,2,4-triazine-4-amine derivatives",,HEPTARES THERAPEUTICS LTD,CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;RICHARDSON CHRISTINE MARY;;BROWN GILES ALBERT,,https://lens.org/170-924-817-408-209,Granted Patent,no,0,0,45,46,0,C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D413/14;;C07D417/04;;C07D417/14;;A61P1/12;;A61P1/16;;A61P13/12;;A61P17/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/20;;A61P25/24;;A61P25/28;;A61P25/30;;A61P27/02;;A61P29/00;;A61P35/00;;A61P43/00;;A61P7/10;;A61P9/00;;A61P9/04;;A61P3/10;;A61K31/4427;;A61K31/506;;A61K31/5355;;C07D253/07;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D413/14;;A61K31/53;;C07D401/04;;A61K31/506;;A61K31/5355;;A61K31/4427;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04;;C07D253/07;;C07D401/04;;C07D413/14;;A61K31/53;;A61K31/5377;;A61K31/5386;;C07D417/04;;C07D417/14,C07D253/07;;A61K31/53;;C07D401/04;;C07D401/12;;C07D401/14;;C07D403/04;;C07D403/12;;C07D405/04;;C07D405/10;;C07D413/04;;C07D417/12;;C07D487/04,,0,0,,,,ACTIVE
41,EP,A1,EP 4126871 A1,190-036-883-346-528,2023-02-08,2023,EP 21715554 A,2021-03-25,US 202062994954 P;;EP 2021057808 W,2020-03-26,TRIAZOLONE COMPOUNDS,,HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/190-036-883-346-528,Patent Application,yes,0,0,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
42,US,A1,US 2023/0146796 A1,013-410-989-971-97X,2023-05-11,2023,US 202117914157 A,2021-03-25,US 202117914157 A;;US 202062994954 P;;EP 2021057808 W,2020-03-26,TRIAZOLONE COMPOUNDS,"Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,HEPTARES THERAPEUTICS LIMITED (2023-03-13),https://lens.org/013-410-989-971-97X,Patent Application,yes,0,0,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04,,0,0,,,,PENDING
43,KR,A,KR 20230049580 A,147-676-779-103-346,2023-04-13,2023,KR 20227037225 A,2021-03-25,US 202062994954 P;;EP 2021057808 W,2020-03-26,트리아졸론 화합물,"화학식 (I)의 트리아졸론 화합물 및 그의 제약상 허용되는 염이 본원에 기재된다. 화학식 (I)의 화합물의 제조 및 사용 방법이 또한 기재된다. 화학식 (I)의 화합물 및 그의 제약상 허용되는 염은, 예를 들어 아데노신 수용체에 의해 매개되는 질환 또는 상태, 예컨대 암, 운동 장애 또는 주의력 장애의 치료에서 아데노신 수용체 길항제로서 유용할 수 있다. TIFFpct00057.tif2429",HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/147-676-779-103-346,Patent Application,no,0,0,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61K31/5377;;A61P35/00,,0,0,,,,PENDING
44,CA,A1,CA 3176944 A1,194-905-696-528-649,2021-09-30,2021,CA 3176944 A,2021-03-25,US 202062994908 P;;EP 2021057806 W,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER","Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY;;CONGREVE MILES STUART;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN,,https://lens.org/194-905-696-528-649,Patent Application,no,0,0,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,A61K31/519;;A61P35/00;;C07D487/04,,0,0,,,,PENDING
45,CN,A,CN 115867550 A,079-207-428-157-418,2023-03-28,2023,CN 202180038087 A,2021-03-25,US 202062994954 P;;EP 2021057808 W,2020-03-26,Triazolone compounds,"Triazolone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described herein. Methods of making and using the compounds of Formula (I) are also described. Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as adenosine receptor antagonists, for example, in the treatment of diseases or conditions mediated by adenosine receptors, such as cancer, dyskinesia or attention disorders.",HEPTARES THERAPEUTICS LTD,G A BROWN;;CONGREVE MICHAEL STUART;;ANDREWS STEPHEN P;;MASON JAMES STUART;;DEFLORIAN FRANK;;SWAIN NICHOLAS A,,https://lens.org/079-207-428-157-418,Patent Application,no,0,0,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04,,0,0,,,,PENDING
46,WO,A1,WO 2021/191380 A1,196-849-736-179-383,2021-09-30,2021,EP 2021057808 W,2021-03-25,US 202062994954 P,2020-03-26,TRIAZOLONE COMPOUNDS,"Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/196-849-736-179-383,Patent Application,yes,11,1,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
47,CA,A1,CA 3177057 A1,028-185-067-250-400,2021-09-30,2021,CA 3177057 A,2021-03-25,US 202062994954 P;;EP 2021057808 W,2020-03-26,TRIAZOLONE COMPOUNDS,"Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/028-185-067-250-400,Patent Application,no,0,0,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,A61K31/519;;A61P35/00;;C07D487/04,,0,0,,,,PENDING
48,AU,A1,AU 2021/240344 A1,101-657-011-596-670,2022-10-27,2022,AU 2021/240344 A,2021-03-25,US 202062994908 P;;EP 2021057806 W,2020-03-26,"5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer","Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY;;CONGREVE MILES STUART;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN,,https://lens.org/101-657-011-596-670,Patent Application,no,0,0,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
49,WO,A1,WO 2021/191378 A1,126-996-341-945-830,2021-09-30,2021,EP 2021057806 W,2021-03-25,US 202062994908 P,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER","Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY;;CONGREVE MILES STUART;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN,,https://lens.org/126-996-341-945-830,Patent Application,yes,9,1,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
50,AU,A1,AU 2021/241886 A1,199-647-927-051-351,2022-10-27,2022,AU 2021/241886 A,2021-03-25,US 202062994954 P;;EP 2021057808 W,2020-03-26,Triazolone compounds,"Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;CONGREVE MILES STUART;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/199-647-927-051-351,Patent Application,no,0,0,8,8,0,A61P35/00;;C07D487/04;;C07D487/04;;A61K31/5377;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
51,US,A1,US 2023/0271964 A1,170-916-320-719-343,2023-08-31,2023,US 202117914245 A,2021-03-25,US 202117914245 A;;US 202062994908 P;;EP 2021057806 W,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER","Described herein are triazalone compounds of Formula (I) and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY;;CONGREVE MILES STUART;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN,HEPTARES THERAPEUTICS LIMITED (2023-03-14),https://lens.org/170-916-320-719-343,Patent Application,yes,0,0,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04,,0,0,,,,PENDING
52,EP,A1,EP 4126872 A1,074-964-556-950-628,2023-02-08,2023,EP 21715861 A,2021-03-25,US 202062994908 P;;EP 2021057806 W,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER",,HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY;;CONGREVE MILES STUART;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN,,https://lens.org/074-964-556-950-628,Patent Application,yes,0,0,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
53,CN,A,CN 115867282 A,163-713-444-500-497,2023-03-28,2023,CN 202180038001 A,2021-03-25,US 202062994908 P;;EP 2021057806 W,2020-03-26,"5-amino-8-(4-pyridinyl)-[1, 2, 4] triazolo [4, 3-c] pyrimidin-3-one compounds for anti-cancer","Triazolone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described herein. Methods of making and using the compounds of Formula (I) are also described. Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as adenosine receptor antagonists, for example, in the treatment of diseases or conditions mediated by adenosine receptors, such as cancer, dyskinesia or attention disorders.",HEPTARES THERAPEUTICS LTD,G A BROWN;;RICHARDSON CRAIG M;;CONGREVE MICHAEL STUART;;PAUL RICHARD;;ANDREWS STEPHEN P;;MASON JAMES STUART,,https://lens.org/163-713-444-500-497,Patent Application,no,0,0,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,A61K31/519,,0,0,,,,PENDING
54,KR,A,KR 20230049579 A,172-784-936-165-538,2023-04-13,2023,KR 20227037221 A,2021-03-25,US 202062994908 P;;EP 2021057806 W,2020-03-26,"암에 대해 사용하기 위한 5-아미노-8--[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물","화학식 (I)의 트리아졸론 화합물 및 그의 제약상 허용되는 염이 본원에 기재된다. 화학식 (I)의 화합물의 제조 및 사용 방법이 또한 기재된다. 화학식 (I)의 화합물 및 그의 제약상 허용되는 염은, 예를 들어 아데노신 수용체에 의해 매개되는 질환 또는 상태, 예컨대 암, 운동 장애 또는 주의력 장애의 치료에서 아데노신 수용체 길항제로서 유용할 수 있다. TIFFpct00091.tif2329",HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;RICHARDSON CHRISTINE MARY;;CONGREVE MILES STUART;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN,,https://lens.org/172-784-936-165-538,Patent Application,no,0,0,8,8,0,C07D487/04;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
55,US,A1,US 2023/0146483 A1,153-520-471-182-857,2023-05-11,2023,US 202117914196 A,2021-03-25,US 202117914196 A;;US 202062994970 P;;EP 2021057807 W,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER","Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;CONGREVE MILES STUART;;RICHARDSON CHRISTINE MARY;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,HEPTARES THERAPEUTICS LIMITED (2023-03-13),https://lens.org/153-520-471-182-857,Patent Application,yes,0,0,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,C07D487/04;;C07D519/00,,0,0,,,,PENDING
56,CN,A,CN 115867280 A,036-477-107-944-306,2023-03-28,2023,CN 202180038082 A,2021-03-25,US 202062994970 P;;EP 2021057807 W,2020-03-26,"5-amino-8-(4-pyridinyl)-[1, 2, 4] triazolo [4, 3-c] pyrimidin-3-one compounds for anti-cancer","Triazolone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described herein. Methods of making and using the compounds of Formula (I) are also described. Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful as adenosine receptor antagonists, for example, in the treatment of diseases or conditions mediated by adenosine receptors, such as cancer, dyskinesia or attention disorders.",HEPTARES THERAPEUTICS LTD,G A BROWN;;CONGREVE MICHAEL STUART;;RICHARDSON CRAIG M;;PAUL RICHARD;;ANDREWS STEPHEN P;;MASON JAMES STUART;;DEFLORIAN FRANK;;SWAIN NICHOLAS A,,https://lens.org/036-477-107-944-306,Patent Application,no,0,0,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,A61K31/501,,0,0,,,,PENDING
57,KR,A,KR 20230051118 A,114-056-584-401-090,2023-04-17,2023,KR 20227037223 A,2021-03-25,US 202062994970 P;;EP 2021057807 W,2020-03-26,"암에 대해 사용하기 위한 5-아미노-8--[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물","화학식 (I)의 트리아졸론 화합물 및 그의 제약상 허용되는 염이 본원에 기재된다. 화학식 (I)의 화합물의 제조 및 사용 방법이 또한 기재된다. 화학식 (I)의 화합물 및 그의 제약상 허용되는 염은, 예를 들어 아데노신 수용체에 의해 매개되는 질환 또는 상태, 예컨대 암, 운동 장애 또는 주의력 장애의 치료에서 아데노신 수용체 길항제로서 유용할 수 있다. TIFFpct00158.tif2227",HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;CONGREVE MILES STUART;;RICHARDSON CHRISTINE MARY;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/114-056-584-401-090,Patent Application,no,0,0,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,C07D487/04;;A61K31/519;;A61P35/00,,0,0,,,,PENDING
58,AU,A1,AU 2021/243725 A1,125-617-361-643-048,2022-10-27,2022,AU 2021/243725 A,2021-03-25,US 202062994970 P;;EP 2021057807 W,2020-03-26,"5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer","Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;CONGREVE MILES STUART;;RICHARDSON CHRISTINE MARY;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/125-617-361-643-048,Patent Application,no,0,0,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,C07D487/04;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/55;;A61P35/00,,0,0,,,,PENDING
59,CA,A1,CA 3177056 A1,000-554-939-272-581,2021-09-30,2021,CA 3177056 A,2021-03-25,US 202062994970 P;;EP 2021057807 W,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER","Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;CONGREVE MILES STUART;;RICHARDSON CHRISTINE MARY;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/000-554-939-272-581,Patent Application,no,0,0,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/55;;A61P35/00;;C07D487/04,,0,0,,,,PENDING
60,EP,A1,EP 4126873 A1,087-275-799-252-814,2023-02-08,2023,EP 21715862 A,2021-03-25,US 202062994970 P;;EP 2021057807 W,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER",,HEPTARES THERAPEUTICS LTD,BROWN GILES ALBERT;;CONGREVE MILES STUART;;RICHARDSON CHRISTINE MARY;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/087-275-799-252-814,Patent Application,yes,0,0,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,C07D487/04;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/55;;A61P35/00,,0,0,,,,PENDING
61,WO,A1,WO 2021/191379 A1,090-387-465-645-161,2021-09-30,2021,EP 2021057807 W,2021-03-25,US 202062994970 P,2020-03-26,"5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER","Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.",ASTRAZENECA AB,BROWN GILES ALBERT;;CONGREVE MILES STUART;;RICHARDSON CHRISTINE MARY;;PAUL REBECCA;;ANDREWS STEPHEN PHILIPPE;;MASON JONATHAN STEPHEN;;DEFLORIAN FRANCESCA;;SWAIN NIGEL ALAN,,https://lens.org/090-387-465-645-161,Patent Application,yes,9,1,8,8,0,C07D487/04;;A61K31/519;;A61P35/00;;C07D487/04;;A61K31/519;;A61P35/00;;C07B2200/05;;C07D487/04;;C07D519/00,C07D487/04;;A61K31/501;;A61K31/506;;A61K31/519;;A61K31/5377;;A61K31/55;;A61P35/00,,0,0,,,,PENDING
62,WO,A3,WO 2007/101212 A3,171-864-753-667-256,2008-11-13,2008,US 2007/0062902 W,2007-02-27,US 77742306 P;;US 67766207 A,2006-02-28,CARRY HANDLE SEAT LATCH FOR CHILD SAFETY SEAT,"A child safety seat assembly (10), including a base (14) for being positioned on a vehicle seat bottom. The base includes an Isofix- type latch (360, 362) for attachment of the base to an Isofix bar of the vehicle seat, and a separate seat belt lock-off (374) for allowing the base to be secured to the vehicle seat by way of the vehicle seat belt. A child earner (12) is provided for being releasably attached to the base. The carrier includes a handle (60) for allowing the carrier to be lifted and carried. The handle includes a latching assembly (72, 74, 76, 78, 79) for releasably locking the carrier to the base and detaching the carrier from the base with a single hand.",BRITAX CHILD SAFETY INC;;OHREN HANS DEREK;;PRZYBYLO PHILLIP;;BUSTLE BENJAMIN SHANE;;CAMPBELL JERRY WAYNE;;KOZLOWSKI JR W JAKE;;MAIER DIETER;;BATCHELOR ADRIAN;;BRINDLEY PAUL;;MASON TROY;;MENDENHALL ANDREW;;ZINK PAUL;;ANDREWS JASON;;TURNER DENNIS,OHREN HANS DEREK;;PRZYBYLO PHILLIP;;BUSTLE BENJAMIN SHANE;;CAMPBELL JERRY WAYNE;;KOZLOWSKI JR W JAKE;;MAIER DIETER;;BATCHELOR ADRIAN;;BRINDLEY PAUL;;MASON TROY;;MENDENHALL ANDREW;;ZINK PAUL;;ANDREWS JASON;;TURNER DENNIS,,https://lens.org/171-864-753-667-256,Search Report,yes,5,0,5,5,0,B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887;;B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887,B60N2/26;;B60N2/42,,0,0,,,,PENDING
63,WO,A2,WO 2007/101212 A2,088-380-361-948-666,2007-09-07,2007,US 2007/0062902 W,2007-02-27,US 77742306 P;;US 67766207 A,2006-02-28,CARRY HANDLE SEAT LATCH FOR CHILD SAFETY SEAT,"A child safety seat assembly, including a base for being positioned on a vehicle seat bottom. The base includes an Isofix-type latch for attachment of the base to an Isofix bar of the vehicle seat, and a separate seat belt lock-off for allowing the base to be secured to the vehicle seat by means of the vehicle seat belt. A child carrier is provided for being releasably attached to the base. The carrier includes a handle for allowing the carrier to be lifted and carried. The handle includes a latching assembly for releasably locking the carrier to the base and detaching the carrier from the base with a single hand.",BRITAX CHILD SAFETY INC;;OHREN HANS DEREK;;PRZYBYLO PHILLIP;;BUSTLE BENJAMIN SHANE;;CAMPBELL JERRY WAYNE;;KOZLOWSKI JR W JAKE;;MAIER DIETER;;BATCHELOR ADRIAN;;BRINDLEY PAUL;;MASON TROY;;MENDENHALL ANDREW;;ZINK PAUL;;ANDREWS JASON;;TURNER DENNIS,OHREN HANS DEREK;;PRZYBYLO PHILLIP;;BUSTLE BENJAMIN SHANE;;CAMPBELL JERRY WAYNE;;KOZLOWSKI JR W JAKE;;MAIER DIETER;;BATCHELOR ADRIAN;;BRINDLEY PAUL;;MASON TROY;;MENDENHALL ANDREW;;ZINK PAUL;;ANDREWS JASON;;TURNER DENNIS,,https://lens.org/088-380-361-948-666,Patent Application,yes,0,10,5,5,0,B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887;;B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887,,,0,0,,,,PENDING
64,US,B2,US 7488034 B2,086-588-446-741-867,2009-02-10,2009,US 74941807 A,2007-05-16,US 74941807 A;;US 67766207 A;;US 77742306 P,2006-02-28,Anti-rebound bar for child safety seat,"A child safety seat assembly, including a base for being positioned on a vehicle seat bottom. An anti-rebound bar is carried by the base and extends outwardly and upwardly from a foot end of the base for engaging a seat back of the vehicle seat to which the seat is attached for retarding inertia-induced rotation of the base and the attached carrier by transmitting rotational force applied to the seat during a sudden change in velocity into the seat back of the vehicle seat onto which the seat is attached.",BRITAX CHILD SAFETY INC,OHREN HANS DEREK;;PRZYBYLO PHILLIP;;BUSTLE BENJAMIN SHANE;;CAMPBELL JERRY WAYNE;;KOZLOWSKI JR W JAKE;;MAIER DIETER;;BATCHELOR ADRIAN;;BRINDLEY PAUL;;MASON TROY;;MENDENHALL ANDREW;;ZINK PAUL;;ANDREWS JASON;;TURNER DENNIS,BRITAX CHILD SAFETY INC (2006-10-24),https://lens.org/086-588-446-741-867,Granted Patent,yes,12,51,5,5,0,B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887;;B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887,A47C31/00;;B60N2/42;;A47D1/00,297/216.11;;297/256.16;;297/256.15;;297/253;;297/183.6,0,0,,,,ACTIVE
65,US,A1,US 2008/0067846 A1,095-840-518-115-872,2008-03-20,2008,US 74941807 A,2007-05-16,US 74941807 A;;US 67766207 A;;US 77742306 P,2006-02-28,ANTI-REBOUND BAR FOR CHILD SAFETY SEAT,"A child safety seat assembly, including a base for being positioned on a vehicle seat bottom. An anti-rebound bar is carried by the base and extends outwardly and upwardly from a foot end of the base for engaging a seat back of the vehicle seat to which the seat is attached for retarding inertia-induced rotation of the base and the attached carrier by transmitting rotational force applied to the seat during a sudden change in velocity into the seat back of the vehicle seat onto which the seat is attached.",BRITAX CHILD SAFETY INC,OHREN HANS D;;PRZYBYLO PHILLIP;;BUSTLE BENJAMIN S;;CAMPBELL JERRY W;;KOZLOWSKI W J JR;;MAIER DIETER;;BATCHELOR ADRIAN;;BRINDLEY PAUL;;MASON TROY;;MENDENHALL ANDREW;;ZINK PAUL;;ANDREWS JASON;;TURNER DENNIS,BRITAX CHILD SAFETY INC (2006-10-24),https://lens.org/095-840-518-115-872,Patent Application,yes,11,9,5,5,0,B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887;;B60N2/2821;;B60N2/2824;;B60N2/2845;;B60N2/2887,B60N2/26,297/256.16,0,0,,,,ACTIVE
66,DE,T5,DE 112021005794 T5,061-384-964-327-306,2023-09-21,2023,DE 112021005794 T,2021-09-17,US 202063108621 P;;US 2021/0050824 W,2020-11-02,Ausrichtungsbekleidung zur Verwendung mit einem vollständig implantierbaren System,"Eine Ausrichtungsweste zum Halten einer externen Spule in einer vorbestimmten Position. Die Ausrichtungsweste kann mindestens einen Befestigungsmechanismus zum Halten der externen Spule in der vorbestimmten Position umfassen. Die Ausrichtungsweste kann auch eine Platte mit einem Befestigungsmechanismus und eine Vielzahl von Gurten umfassen, wobei die Frontplatte an mindestens einem der Vielzahl von Gurten gesichert ist.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLEN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,,https://lens.org/061-384-964-327-306,Patent Application,no,2,0,3,3,0,A61M60/875;;A61M2209/088;;H02J50/10;;A61M60/178;;A61M60/232;;A61M2205/8243;;H02J2310/23;;H02J50/10;;H02J2310/23;;A61M60/232;;A61M60/875;;A61M60/178;;A61M2205/8243;;A61M2209/088,A41D1/00;;A61M60/122;;H02J50/10,,0,0,,,,PENDING
67,US,A1,US 2024/0017054 A1,160-635-251-305-011,2024-01-18,2024,US 202118251359 A,2021-09-17,US 202118251359 A;;US 202063108621 P;;US 2021/0050824 W,2020-11-02,ALIGNMENT GARMENT FOR USE WITH A FULLY IMPLANTABLE SYSTEM,"An alignment vest for holding an external coil in a predetermined location. The alignment vest may comprise at least one attachment mechanism for holding the external coil in the predetermined location. The alignment vest may also comprise a panel having a fastening mechanism and a plurality of straps, the front panel being secured to at least one of the plurality of straps.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLENN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,INNOVIA TECHNOLOGY LTD (2023-07-06);;MEDTRONIC INC (2020-11-30),https://lens.org/160-635-251-305-011,Patent Application,yes,0,0,3,3,0,A61M60/875;;A61M2209/088;;H02J50/10;;A61M60/178;;A61M60/232;;A61M2205/8243;;H02J2310/23;;H02J50/10;;H02J2310/23;;A61M60/232;;A61M60/875;;A61M60/178;;A61M2205/8243;;A61M2209/088,A61M60/875;;A61M60/178;;A61M60/232;;H02J50/10,,0,0,,,,PENDING
68,WO,A1,WO 2022/093422 A1,009-062-232-207-512,2022-05-05,2022,US 2021/0050824 W,2021-09-17,US 202063108621 P,2020-11-02,ALIGNMENT GARMENT FOR USE WITH A FULLY IMPLANTABLE SYSTEM,"An alignment vest for holding an external coil in a predetermined location. The alignment vest may comprise at least one attachment mechanism for holding the external coil in the predetermined location. The alignment vest may also comprise a panel having a fastening mechanism and a plurality of straps, the front panel being secured to at least one of the plurality of straps.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLEN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,,https://lens.org/009-062-232-207-512,Patent Application,yes,4,0,3,3,0,A61M60/875;;A61M2209/088;;H02J50/10;;A61M60/178;;A61M60/232;;A61M2205/8243;;H02J2310/23;;H02J50/10;;H02J2310/23;;A61M60/232;;A61M60/875;;A61M60/178;;A61M2205/8243;;A61M2209/088,A61M60/122;;A61M60/875;;H02J50/10,,0,0,,,,PENDING
69,US,A1,US 2024/0001106 A1,113-718-818-154-437,2024-01-04,2024,US 202118251328 A,2021-09-21,US 202118251328 A;;US 202063108618 P;;US 2021/0051200 W,2020-11-02,ALIGNMENT GARMENT FOR USE WITH A FULLY IMPLANTABLE SYSTEM,An alignment garment for holding an external coil in a predetermined location. The alignment garment may comprise an attachment mechanism for holding the external coil in the predetermined location. The alignment garment may also have a plurality of straps with a first strap in the plurality of straps being secured to the attachment mechanism and a second strap of the plurality of straps being secured to the attachment mechanism.,MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLENN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,INNOVIA TECHNOLOGY LTD (2023-07-06);;MEDTRONIC INC (2020-11-30),https://lens.org/113-718-818-154-437,Patent Application,yes,0,0,3,3,0,A61M60/875;;A61N1/3787;;H02J50/10;;H02J2310/23;;A61M60/216;;A61M60/178;;A61M2209/088;;A61M60/875;;A61M2209/088,A61M60/875,,0,0,,,,PENDING
70,DE,T5,DE 112021005772 T5,023-251-875-282-196,2023-09-21,2023,DE 112021005772 T,2021-09-17,US 202063108625 P;;US 2021/0050829 W,2020-11-02,Befestigungsmechanismus für Ausrichtungskleidungsstück zur Verwendung mit einem vollständig implantierbaren System,"Ein Befestigungsmechanismus, der an einem Kleidungsstück zum Halten einer externen Spule an einer vorbestimmten Stelle sicherbar ist, wobei der Befestigungsmechanismus folgendes umfasst: einen Körper mit einer Vielzahl von Vorsprüngen, wobei die Vielzahl von Vorsprüngen konfiguriert ist, um innerhalb einer Öffnung der externen Spule aufgenommen zu werden; und ein Verankerungselement, das konfiguriert ist, um an dem Kleidungsstück gesichert zu werden, um die externe Spule an dem Kleidungsstück zu sichern.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLEN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,,https://lens.org/023-251-875-282-196,Patent Application,no,2,0,3,3,0,A61M60/875;;A61M2209/088;;A61M60/178;;A61M60/232;;A61M2205/8243;;A61M60/875;;A61M2205/8243;;A61M2209/088,A61M60/875;;A61M60/122;;A61M60/449,,0,0,,,,PENDING
71,WO,A1,WO 2022/093423 A1,047-447-567-092-804,2022-05-05,2022,US 2021/0050829 W,2021-09-17,US 202063108625 P,2020-11-02,ATTACHMENT MECHANISM FOR ALIGNMENT GARMENT FOR USE WITH A FULLY IMPLANTABLE SYSTEM,"An attachment mechanism securable to a garment for holding an external coil in a predetermined location, the attachment mechanism comprising: a body with a plurality of protrusions, the plurality of protrusions configured to be received within an aperture of the external coil; and an anchoring element configured to be secured to the garment to secure the external coil to the garment.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLEN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,,https://lens.org/047-447-567-092-804,Patent Application,yes,5,0,3,3,0,A61M60/875;;A61M2209/088;;A61M60/178;;A61M60/232;;A61M2205/8243;;A61M60/875;;A61M2205/8243;;A61M2209/088,A61M60/122;;A61M60/875,,0,0,,,,PENDING
72,US,A1,US 2023/0405305 A1,107-633-591-743-148,2023-12-21,2023,US 202118251342 A,2021-09-17,US 202118251342 A;;US 202063108625 P;;US 2021/0050829 W,2020-11-02,ATTACHMENT MECHANISM FOR ALIGNMENT GARMENT FOR USE WITH A FULLY IMPLANTABLE SYSTEM,"An attachment mechanism securable to a garment for holding an external coil in a predetermined location, the attachment mechanism comprising: a body with a plurality of protrusions, the plurality of protrusions configured to be received within an aperture of the external coil; and an anchoring element configured to be secured to the garment to secure the external coil to the garment.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLENN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,INNOVIA TECHNOLOGY LTD (2023-07-10);;MEDTRONIC INC (2020-11-30),https://lens.org/107-633-591-743-148,Patent Application,yes,0,0,3,3,0,A61M60/875;;A61M2209/088;;A61M60/178;;A61M60/232;;A61M2205/8243;;A61M60/875;;A61M2205/8243;;A61M2209/088,A61M60/875,,0,0,,,,PENDING
73,WO,A1,WO 2022/093435 A1,155-945-713-843-950,2022-05-05,2022,US 2021/0051200 W,2021-09-21,US 202063108618 P,2020-11-02,ALIGNMENT GARMENT FOR USE WITH A FULLY IMPLANTABLE SYSTEM,An alignment garment for holding an external coil in a predetermined location. The alignment garment may comprise an attachment mechanism for holding the external coil in the predetermined location. The alignment garment may also have a plurality of straps with a first strap in the plurality of straps being secured to the attachment mechanism and a second strap of the plurality of straps being secured to the attachment mechanism.,MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLEN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,,https://lens.org/155-945-713-843-950,Patent Application,yes,6,0,3,3,0,A61M60/875;;A61N1/3787;;H02J50/10;;H02J2310/23;;A61M60/216;;A61M60/178;;A61M2209/088;;A61M60/875;;A61M2209/088,A61N1/378;;A61M60/875;;H02J50/00,,0,0,,,,PENDING
74,DE,T5,DE 112021005771 T5,041-079-936-143-909,2023-08-17,2023,DE 112021005771 T,2021-09-21,US 202063108618 P;;US 2021/0051200 W,2020-11-02,Ausrichtungsweste zur Verwendung mit einem vollständig implantierbaren System,"Eine Ausrichtungsweste zum Halten einer externen Spule an einer vorbestimmten Stelle. Die Ausrichtungsweste kann einen Befestigungsmechanismus umfassen, um die externe Spule an der vorbestimmten Stelle zu halten. Die Ausrichtungsweste kann auch eine Vielzahl von Riemen aufweisen, wobei ein erster Riemen der Vielzahl von Riemen an dem Befestigungsmechanismus befestigt ist und ein zweiter Riemen der Vielzahl von Riemen an dem Befestigungsmechanismus befestigt ist.",MEDTRONIC INC,NELSON STEPHEN M;;PEICHEL DAVID J;;SCHILLING ERIC A;;MASON NATHANAEL O;;MOIR ROBERT SCADDING;;CLARKE LILLIAN E;;AKRAM ISMAIL;;LE FAOU GLEN;;ANDREWS RICHARD JAMES;;HANUSAIK JORDI VILANOVA;;WILSON ANNA REBECCA LOUISE;;RODRIGUES ARRON CARMO DO ROSARIO,,https://lens.org/041-079-936-143-909,Patent Application,no,2,0,3,3,0,A61M60/875;;A61N1/3787;;H02J50/10;;H02J2310/23;;A61M60/216;;A61M60/178;;A61M2209/088;;A61M60/875;;A61M2209/088,A61N1/378;;A61M60/122;;A61M60/40;;A61M60/875;;H02J50/10;;H02J50/90,,0,0,,,,PENDING
